

CURRICULUM VITAE

DAVID STEPHEN CELERMAJER AO

***MB BS (Hons I, Sydney) MSc (Oxon) PhD (Lond) FRACP FCSANZ
FHKCC(Hon) FAHA DSc (Sydney) FAA***

Scandrett Professor of Cardiology, University of Sydney

SEPTEMBER 2017

PERSONAL DETAILS

Name: **DAVID STEPHEN CELERMAJER**

Address: 45 Olola Avenue Tel: 612 93372636
Vaucluse, 2030 Fax: 612 93373290
Sydney, Australia
E-mail: david.celermajer@sswahs.cs.nsw.gov.au

Date of Birth: 8th December 1961

Nationality: Australian

Marital Status: Married, 3 Adult children

PRESENT APPOINTMENTS

- Scandrett Professor of Cardiology and Head of Discipline of Cardiology, The University of Sydney
- Director of Echocardiography and Clinical Academic Cardiologist, Royal Prince Alfred Hospital (RPAH)
- Director of Adult Congenital Heart Services, RPAH
- Director of Pulmonary Hypertension Services, RPAH
- Honorary Staff Cardiologist, The Children's Hospital, Westmead, Sydney
- Clinical Director and Group Leader, Clinical Research, The Heart Research Institute, Sydney

ACADEMIC RECORD

SYDNEY GRAMMAR SCHOOL (1973-1978)

1972	Scholarship to Sydney Grammar School
1976	Junior Knox Prize for Dux of the Junior School
1977	Australian Mathematics Olympiad - second place
1978	Senior Knox Prize for <u>DUX OF SCHOOL</u>

UNIVERSITY OF SYDNEY (1979-1983)

<u>Year</u>	<u>Subject</u>	<u>Grade</u>	<u>Position In Yr/250</u>
1979	Physics	High Distinction	1st
Med I	Chemistry	High Distinction	1st
(1st Overall)	Intro. Med. Science	High Distinction	1st
1980	Anatomy	High Distinction	1st
Med II	Biochemistry	High Distinction	2nd
(1st Overall)	Histology & Embryology	High Distinction	2nd
	Physiology	High Distinction	2nd
	Behavioural Sciences	Credit	6th
	Pharmacology	Distinction	6th
1981	Pathology	High Distinction	1st
Med III	Bacteriology	High Distinction	1st
(1st Overall)	Clinical Sciences	High Distinction	1st
1982	Paediatrics	High Distinction	4th
Med IV	Psychiatry	High Distinction	1st
(1st Overall)	Obstetrics & Gynaecology	Credit	3rd
	Community Medicine	Distinction	2nd
1983 Med V	Medicine	Distinction	1st
(1st Overall)	Surgery	High Distinction	1st

At Graduation - UNIVERSITY MEDAL AND FIRST CLASS HONOURS

PRIZES - UNIVERSITY OF SYDNEY

1. J.T. Wilson Memorial Prize for Anatomy
2. Herbert John Wilkinson Prize for Anatomy
3. Inglis and Ward Prize for Proficiency in Pathology and Bacteriology
4. Allan Douglas Gillies Prize for Pathology
5. Parkinson Memorial Prize for Pathology
6. Norton Manning Memorial Prize for Proficiency in Psychiatry
7. Harry J. Clayton Memorial Prize for Proficiency in Medicine and Clinical Surgery
8. Hinder Memorial Prize for Proficiency in Surgery and Clinical Surgery
9. Harold John Ritchie Prize for Proficiency in Clinical Medicine
10. William Henry and Elize Alice Sharp Prize for Proficiency in Surgery/Clinical Surgery
11. Robert Scot Skirving Memorial Prize for Medicine and Surgery
12. The Dagmar Berne Prize for Proficiency in the Final Year
13. The A.E. Mills Graduation Prize for First Place in Honours List

UNIVERSITY OF OXFORD (1985)

Master of Science (by Research in Clinical Biochemistry) - "NMR and biochemical aspects of alcohol induced cardiac and skeletal myopathy in animals and man."

UNIVERSITY OF LONDON (1990-1993)

Doctor of Philosophy - "Non-invasive studies of arterial physiology in children and adults at risk of atherosclerosis."

UNIVERSITY OF SYDNEY (2006)

Doctor of Science - "The biology and physiology of arteries in health and disease."

SCHOLARSHIPS AND FELLOWSHIPS

1979 - 1983	E. Trenchard Miller Scholarship for Academic Achievement
1980 - 1981	G.S. Caird No. I and No. II, Renwick Scholarships
1983	<u>RHODES SCHOLARSHIP</u> for New South Wales
1990	Sir Zelman Cowen Medical Foundation Overseas Research Fellowship
1990	Admitted as a Fellow of the Royal Australasian College of Physicians
1992	Cardiac Society of Australia and New Zealand Bursary
1994 -1995	R.D. Wright Fellowship (NHMRC)
1997	Admitted as a Fellow of the American Heart Association
1996 - 2002	Medical Foundation Fellow, University of Sydney
2005	Honorary fellowship of the Hong Kong College of Cardiology
2006	Admitted as a Fellow of the Australian Academy of Science

2007 Admitted as a Fellow of the Cardiac Society of Australia and New Zealand

PAST APPOINTMENTS

1984 Internship, Royal Prince Alfred Hospital

1986 Rotating resident terms in medical specialty units, RPAH

1987 Medical Registrar (RPAH) - Cardiology (6 months)
- Nephrology (6 months)

1988 Medical Registrar - Thoracic Medicine (6 months)
- Cardiology (6 months)

1989 Cardiology Registrar (RPAH)
-including 6 months secondment to the Royal Alexandra Hospital for Children

1990 Cardiothoracic Registrar, RPAH (6 months)
Cardiovascular Fellow, Hospital for Sick Children, Great Ormond Street, London (6 months)

1991-1993 Cardiovascular Research Fellow and Senior Registrar in Paediatric Cardiology, Hospital for Sick Children, Great Ormond Street, London

Senior Registrar in Cardiology, St. Bartholomew's Hospital, West Smithfield, London

1994-1995 Senior Clinical Scientist, The Heart Research Institute, Sydney
Clinical Senior Lecturer, Department of Medicine, University of Sydney
Associate Cardiologist, RPAH

1996-1999 Associate Professor of Medicine and Medical Foundation Fellow, University of Sydney

1999-2002 Professor of Medicine and Medical Foundation Fellow, University of Sydney

2000-2004 Director of Research, Royal Prince Alfred Hospital (RPAH), Sydney

2000-2005 Member, Research Committee, Heart Foundation of Australia

2005-2011 Chairman, Research Committee, Heart Foundation of Australia

TEACHING AND SUPERVISION

TEACHING ACTIVITIES

1987-9	Lectures	Cardiothoracic Nursing courses; RPAH General Nursing course; School of Nursing, Glebe
	Lectures	Medicine IV; general medical topics Medicine VI; cardiovascular topics Interns, RPAH; general medical topics
	Tutorials	Medicine IV; General medicine (RPAH)
1990-3	Lectures	Paediatric Cardiology courses, Great Ormond Street Hospital (GOS), London Cardiology in the Young courses, Royal Brompton Hospital, London
	Lectures	Cardiothoracic nursing courses, GOS SHO teaching series, GOS
1994-2014	Lectures	Paediatric Cardiology Update weekends College of Physicians Update weekends Postgraduate Committee Course for Overseas Trained Doctors, 1995-7 Cardiology lectures, UMP year 6, 1994-2001 Echocardiography lectures, SMP year 1, 1997-2011
	Lectures	Specialist Weekend Symposia (on congenital and acquired heart disease), 1994-2011 Heart Care Workshops for NSW General Practitioners, 1994-6 Coronary Care teaching sessions, 1994-2011 FRACP Part I teaching sessions, 1994-2011 Cardiothoracic Unit Meetings, RPAH (inhaled nitric oxide; postoperative arrhythmias), 1994-2011 Cardiology Unit Presentations, RPAH (numerous), 1994-2011
1994 - Present	Tutorials	Medicine I-IV - General Medicine (RPAH) Medicine I-IV - Cardiology (RPAH) FRACP Clinical Tutorials for viva candidates (RPAH) Examiner for Medicine III, IV and VI, University of Sydney and then for SMP Years 1, 3 Development of Atherosclerosis Problem (problem 4.04), Sydney Medical Program, University of Sydney Basic Physician Training lectures – Post-Graduate Committee in Medicine
1998-2013		Examiner for the RACP in Internal Medicine

RESEARCH SUPERVISION

Dr Mark Adams - PhD supervisor, from February 1994-1997

Mr Yen Tai - Summer vacation scholar, 1994-1995

Dr Jane McCrohon - PhD supervisor, from February 1996-1999

Ms Sonia Kariappa - Summer vacation scholar, 1995-1996

Dr Mark Herman - Clinical research supervisor, 1995-1996

Ms Robyn McCredie -Clinical trials co-ordinator, Research Assistant, from July 1994

Ms Kaye Griffiths - Research Sonographer, Research Assistant, 1997-2004

Mrs Shirley Nakhla - Research Assistant, from 1996

Dr Mark Sader - Clinical research supervisor, 1997-1998; PhD supervisor from 1999

Dr Stephanie Wilson - PhD supervisor, from January 1997

Ms Gemma Figtree - BScMed associate supervisor, 1997

Dr Olli Raitakari - Post doctoral supervisor, 1997-1999

Dr Stephen Wu - Summer vacation scholar, 1997-1998

Dr Meredith Sheil - PhD supervisor, from October 1997

Dr Antony Lau - PhD associate supervisor, from January 1998

Dr Jo Dee Lattimore - Clinical research supervisor, from 1998; PhD supervisor from 2000

Dr Jens Kilian - Clinical research supervisor, from January 1999; PhD supervisor from 2001

Dr Upul Premawardhana – Echocardiography Fellow, from January 1999

Ms Kristine Chan – Research Assistant, from January 1999

Dr Ted Wu - Associate supervisor, PhD studies, from January 1999

Dr David Lai - Associate supervisor, PhD studies, from January 1999

Dr Matthias Langenfeld – Post doctoral supervisor, from March 1999

Ms Karolyn Ruc – Research Assistant, from July 1999

Dr WB Chan – Post doctoral supervisor, from September 1999

Mr Michael Skilton – Research Assistant, from 1999; PhD supervisor from March 2002

Dr Martin Ng – PhD supervisor, from February 2000

Dr Dominic Mou – Echocardiography Fellow, from January 2000

Dr Kim Greaves – Echocardiography Fellow, from October 2001

Mr Jason Harmer – Research Assistant, from April 2002, PhD supervisor from February 2006

Dr Pia Lundman – Post doctoral supervisor, from January 2003

Mr Daniel Sieveking – Research Assistant, March 2003, PhD supervisor from January 2006

Dr Raj Puranik – PhD supervisor, from January 2004

Ms Elizabeth Maher – Research Sonographer, Research Assistant, from June 2004

Ms Joanna Faulkner – Research Assistant, from January 2005 to July 2005

Dr Julian Ayer – PhD supervisor, from January 2005

Ms Sharmila Selvaratnam – Research Assistant, from May 2005 to November 2007

Dr Sanjay Patel – PhD supervisor, from January 2006

Dr Rahn IIsar – PhD supervisor, from January 2006

Ms Rebecca Micallef – Research Assistant, from January 2008

Dr Bernie Changsiri – PhD supervisor from February 2008

Mr Shamus O’Meagher – Research Assistant, from September 2008

Dr Rachael Cordina – PhD supervisor from February 2009

Dr Young Yu – PhD supervisor from February 2010

Dr Jamie Morton – PhD supervisor from February 2010

Dr Edmund Lau – PhD supervisor from July 2010

Dr Preeti Choudhary – PhD Supervisor from Feb 2012

Dr Shareen Jaijee - PhD Supervisor from Feb 2012

Dr Carla Canniffe – PhD Supervisor (UCD student) from Nov 2013

Dr Tripura Srinivas – M Sc Supervisor from August 2014

Dr Clare Arnott – PhD Supervisor from Feb 2014

Dr Kelly Stanton – PhD Supervisor from Feb 2014

Dr Jenny Barraclough - PhD Supervisor from Feb 2015

Dr Sean Lal – PhD Supervisor from Feb 2015

Dr Ben Moore – PhD Supervisor from July 2017

Dr Mark Dennis – PhD Supervisor from July 2017

SUPERVISION – DEGREES COMPLETED

Dr Mark Adams, PhD – 1997
Dr Jane McCrohon, PhD – 1999
Dr Stephanie Wilson, PhD – 2001
Dr Upul Premawardhana, MMed – 2001
Dr Mark Sader, PhD – 2003
Dr Martin Ng, PhD – 2003
Dr JoDee Lattimore, PhD – 2004
Dr Michael Skilton, PhD – 2005
Dr Jens Kilian, PhD – 2005
Dr Meredith Sheil, PhD – 2006
Dr Raj Puranik, PhD – 2007
Dr Clara Chow, PhD – 2007
Dr Dan Sieveking, PhD – 2009
Dr Rahn Ilsar, PhD – 2010
Dr Sanjay Patel, PhD – 2010
Dr Julian Ayer, PhD – 2010
Dr Bernie Changsiri, PhD – 2012
Dr Rachael Cordina – 2013
Dr Jamie Morton – 2013
Dr Shamus O’Meagher – 2014
Dr Edmund lau - 2014
Dr Jason Harmer – 2015
Dr Tepura Sharma, PhD – 2016
Dr Shareen Jaijee, PhD – 2017
Dr Preeti Choudhory, PhD - 2017

PHD THESES EXAMINED

Dr Helena Teede – Monash University – 2000
Dr Stephen Worthley – Adelaide University – 2000
Dr Paul Manwaring – University of NSW – 2001
Dr Brendan McQuillan – University of Western Australia – 2001
Dr Pia Lundman – Karolinska Institute, Sweden – 2001
Dr Omar Farouque – Monash University – 2002

Ms Katie Watts – University of Western Australia – 2004

Dr Angela Makris – University of Sydney – 2006

Dr Nay Htun – Monash University – 2015

CURRENT OR RECENT SCIENTIFIC REVIEWER (*inter alia*)

New England Journal of Medicine

The Lancet

Journal of the American Medical Association

Circulation

Journal of the American College of Cardiology

Arteriosclerosis, Thrombosis and Vascular Biology

Atherosclerosis

American Heart Journal

Coronary Artery Disease

Paediatric Cardiology

British Heart Journal/Heart

Journal of the American Society of Nephrology

Medical Journal of Australia

Diabetes Research and Clinical Practice

Cardiovascular Drugs and Therapy

Cardiovascular Research

American Journal of Cardiology

Clinical and Experimental Physiology and Pharmacology

Heart, Lung and Circulation

National Health and Medical Research Council of Australia

National Research Council of New Zealand

National Heart Foundation of Australia

EDITORIAL BOARDS

Circulation, 2007-2016

Journal of the American College of Cardiology, 2005-present

European Heart Journal, 2008-2010; International Associate Editor (from Nov 2013)

Structural Heart Disease, 2016 - present

Heart, 2006-present

Congenital Heart Disease: from Fetus to Adult, 2006-present

Heart, Lung and Circulation, 2006-2014

Cardiovascular Journal of South Africa, 2005-present

RESEARCH RECORD

PUBLICATIONS (excluding abstracts)

1. **Celermajer DS**, Mellis CM. Bronchiolitis in infancy. *Mod Med*. 1984;27-37.
2. **Celermajer DS**, Thorner PS, Baumal R, Arbus GS. Sex differences in childhood lupus nephritis. *Am J Dis Child*. 1984;138(6):586-8.
3. Thorner PS, Arbus GS, **Celermajer DS**, Baumal R. Focal segmental glomerulosclerosis and progressive renal failure associated with a unilateral kidney. *Pediatrics*. 1984;73(6):806-10.
4. **Celermajer DS**, Bailey BP, Beetson R, Zeng GE, Bernstein L, Hughes CF. Emergency coronary artery bypass surgery following coronary angioplasty--favourable medium term outcome after eight years' experience. *Aust N Z J Med*. 1991;21(2):211-6.
5. **Celermajer DS**, Boyer MJ, Bailey BP, Tattersall MH. Pericardiocentesis for symptomatic malignant pericardial effusion: a study of 36 patients. *Med J Aust*. 1991;154(1):19-22.
6. **Celermajer DS**, Cullen S, Deanfield JE, Sullivan ID. Congenitally corrected transposition and Ebstein's anomaly of the systemic atrioventricular valve: association with aortic arch obstruction. *J Am Coll Cardiol*. 1991;18(4):1056-8.
7. **Celermajer DS**, Deanfield JE. Adults with congenital heart disease (Editorial). *BMJ*. 1991;303(6815):1413-4.
8. **Celermajer DS**, Sholler GF, Howman-Giles R, Celermajer JM. Myocardial infarction in childhood: clinical analysis of 17 cases and medium term follow up of survivors. *Br Heart J*. 1991;65(6):332-6.
9. **Celermajer DS**, Sholler GF, Hughes CF, Baird DK. Persistent ductus arteriosus in adults. A review of surgical experience with 25 patients. *Med J Aust*. 1991;155(4):233-6.
10. Cullen S, **Celermajer DS**, JE. D. Exercise in congenital heart disease. *Cardiology in the young*. 1991;1:129-35.
11. **Celermajer DS**, Cullen S, Sullivan ID, Spiegelhalter DJ, Wyse RK, Deanfield JE. Outcome in neonates with Ebstein's anomaly. *J Am Coll Cardiol*. 1992;19(5):1041-6.
12. **Celermajer DS**, Dodd SM, Greenwald SE, Wyse RK, Deanfield JE. Morbid anatomy in neonates with Ebstein's anomaly of the tricuspid valve: pathophysiologic and clinical implications. *J Am Coll Cardiol*. 1992;19(5):1049-53.
13. **Celermajer DS**, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. *Lancet*. 1992;340(8828):1111-5.
14. Burch M, Iacovides P, Habibi R, DS C. Non cardiac cyanosis in left isomerism: report of two cases of multiple pulmonary arteriovenous malformations. *Cardiology in the young*. 1993(3):64-6.
15. **Celermajer DS**, JE D. Cardiology. In: Edward Arnold, editor. *The practice of adolescent medicine* 1993.

16. **Celermajer DS**, Cullen S, Deanfield JE. Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. *Circulation*. 1993;87(2):440-6.
17. **Celermajer DS**, Cullen S, Deanfield JE. In vivo detection of endothelium dependent and independent pulmonary artery relaxation in children. *Br Heart J*. 1993;69(4):298-302.
18. **Celermajer DS**, Deanfield JE. Employment and insurance for young adults with congenital heart disease. *Br Heart J*. 1993;69(6):539-43.
19. **Celermajer DS**, Robinson JT, Taylor JF. Vascular access in previously catheterised children and adolescents: a prospective study of 131 consecutive cases. *Br Heart J*. 1993;70(6):554-7.
20. **Celermajer DS**, Sorensen K, Ryalls M, Robinson J, Thomas O, Leonard JV, Deanfield JE. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. *J Am Coll Cardiol*. 1993;22(3):854-8.
21. **Celermajer DS**, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J, Deanfield JE. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. *Circulation*. 1993;88(5 Pt 1):2149-55.
22. Burch M, Siddiqi SA, **Celermajer DS**, Scott C, Bull C, Deanfield JE. Dilated cardiomyopathy in children: determinants of outcome. *Br Heart J*. 1994;72(3):246-50.
23. **Celermajer DS**, Bull C TJ, Cullen S, Vassilikos VP, Sullivan ID, Allan L, Nihoyannopoulos P, Somerville J, JE D. Ebstein's anomaly: presentation and outcome from fetus to adult. *J Am Coll Cardiol* 1994(23):170-6.
24. 24. **Celermajer DS**, Sorensen KE, JE D. Atherosclerosis a disease that begins in childhood. *Cardiology in the young*. 1994(4):222-7.
25. **Celermajer DS**, Bull C, Till JA, Cullen S, Vassilikos VP, Sullivan ID, Allan L, Nihoyannopoulos P, Somerville J, Deanfield JE. Ebstein's anomaly: presentation and outcome from fetus to adult. *J Am Coll Cardiol*. 1994;23(1):170-6.
26. **Celermajer DS**, Dollery C, Burch M, Deanfield JE. Role of endothelium in the maintenance of low pulmonary vascular tone in normal children. *Circulation*. 1994;89(5):2041-4.
27. **Celermajer DS**, Sorensen KE, Barley J, Jeffrey S, Carter N, Deanfield J. Angiotensin-converting enzyme genotype is not associated with endothelial dysfunction in subjects without other coronary risk factors. *Atherosclerosis*. 1994;111(1):121-6.
28. **Celermajer DS**, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. *J Am Coll Cardiol*. 1994;24(6):1468-74.
29. **Celermajer DS**, Sorensen KE, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Deanfield JE. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. *J Am Coll Cardiol*. 1994;24(2):471-6.
30. **Celermajer DS**, Spiegelhalter DJ, Deanfield M, Deanfield JE. Variability of episodic ST segment depression in chronic stable angina: implications for individual and group trials

- of therapeutic efficacy. *J Am Coll Cardiol.* 1994;23(1):66-73.
31. Cullen S, **Celermajer DS**, Franklin RC, Hallidie-Smith KA, Deanfield JE. Prognostic significance of ventricular arrhythmia after repair of tetralogy of Fallot: a 12-year prospective study. *J Am Coll Cardiol.* 1994;23(5):1151-5.
 32. DS C. Employment and Insurance. In: Redington AN, Oldershaw P, editors. *Congenital Heart Disease In Adults.* London: WB Saunders; 1994. p. 237-47.
 33. Gardiner HM, **Celermajer DS**, Sorensen KE, Georgakopoulos D, Robinson J, Thomas O, Deanfield JE. Arterial reactivity is significantly impaired in normotensive young adults after successful repair of aortic coarctation in childhood. *Circulation.* 1994;89(4):1745-50.
 34. Joffe H, Georgakopoulos D, **Celermajer DS**, Sullivan ID, Deanfield JE. Late ventricular arrhythmia is rare after early repair of tetralogy of Fallot. *J Am Coll Cardiol.* 1994;23(5):1146-50.
 35. Lee PJ, **Celermajer DS**, Robinson J, McCarthy SN, Betteridge DJ, Leonard JV. Hyperlipidaemia does not impair vascular endothelial function in glycogen storage disease type 1a. *Atherosclerosis.* 1994;110(1):95-100.
 36. Miller OI, **Celermajer DS**, Deanfield JE, Macrae DJ. Guidelines for the safe administration of inhaled nitric oxide. *Arch Dis Child Fetal Neonatal Ed.* 1994;70(1):F47-9.
 37. Miller OI, **Celermajer DS**, Deanfield JE, Macrae DJ. Very-low-dose inhaled nitric oxide: a selective pulmonary vasodilator after operations for congenital heart disease. *J Thorac Cardiovasc Surg.* 1994;108(3):487-94.
 38. Sorensen KE, **Celermajer DS**, Georgakopoulos D, Hatcher G, Betteridge DJ, Deanfield JE. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. *J Clin Invest.* 1994;93(1):50-5.
 39. Adams MR, Forsyth CJ, Jessup W, Robinson J, **Celermajer DS**. Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men. *J Am Coll Cardiol.* 1995;26(4):1054-61.
 40. Adams MR, Nakagomi A, Keech A, Robinson J, McCredie R, Bailey BP, Freedman SB, **Celermajer DS**. Carotid intima-media thickness is only weakly correlated with the extent and severity of coronary artery disease. *Circulation.* 1995;92(8):2127-34.
 41. **Celermajer DS**. Detecting and treating early atherosclerosis. *Med J Aust.* 1995;162(4):172-3.
 42. Miller OI, Tang SF, Keech A, **Celermajer DS**. Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide. *Lancet.* 1995;346(8966):51-2.
 43. Sorensen KE, **Celermajer DS**, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Thomas O, Deanfield JE. Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. *Br Heart J.* 1995;74(3):247-53.
 44. Adams MR, Robinson J, Sorensen KE, Deanfield JE, **Celermajer DS**. Normal ranges for brachial artery flow-mediated dilation: a non-invasive ultrasound test of arterial endothelial function. *J Vasc Invest* 1996(2):146-50.
 45. **Celermajer DS**, Adams MR, Clarkson P, Robinson J, McCredie R, Donald A, Deanfield JE.

- Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. *N Engl J Med.* 1996;334(3):150-4.
46. **Celermajer DS**, Pressley L, Robinson PJ, Hawker RE. "Grown-ups" with congenital heart disease. *Med J Aust.* 1996;164(12):708-9.
 47. Clarkson P, Adams MR, Powe AJ, Donald AE, McCredie R, Robinson J, McCarthy SN, Keech A, **Celermajer DS**, Deanfield JE. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. *J Clin Invest.* 1996;97(8):1989-94.
 48. Clarkson P, **Celermajer DS**, Donald AE, Sampson M, Sorensen KE, Adams M, Yue DK, Betteridge DJ, Deanfield JE. Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. *J Am Coll Cardiol.* 1996;28(3):573-9.
 49. McCrohon JA, Adams MR, McCredie RJ, Robinson J, Pike A, Abbey M, Keech AC, **Celermajer DS**. Hormone replacement therapy is associated with improved arterial physiology in healthy post-menopausal women. *Clin Endocrinol (Oxf).* 1996;45(4):435-41.
 50. Nakagomi A, **Celermajer DS**, Lumley T, Freedman SB. Angiographic severity of coronary narrowing is a surrogate marker for the extent of coronary atherosclerosis. *Am J Cardiol.* 1996;78(5):516-9.
 51. Adams MR, Jessup W, **Celermajer DS**. Cigarette smoking is associated with increased human monocyte adhesion to endothelial cells: reversibility with oral L-arginine but not vitamin C. *J Am Coll Cardiol.* 1997;29(3):491-7.
 52. Adams MR, Jessup W, Hailstones D, **Celermajer DS**. L-arginine reduces human monocyte adhesion to vascular endothelium and endothelial expression of cell adhesion molecules. *Circulation.* 1997;95(3):662-8.
 53. Adams MR, McCredie R, Jessup W, Robinson J, Sullivan D, **Celermajer DS**. Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. *Atherosclerosis.* 1997;129(2):261-9.
 54. **Celermajer DS**. Endothelial dysfunction: does it matter? Is it reversible? *J Am Coll Cardiol.* 1997;30(2):325-33.
 55. Clarkson P, **Celermajer DS**, Powe AJ, Donald AE, Henry RM, Deanfield JE. Endothelium-dependent dilatation is impaired in young healthy subjects with a family history of premature coronary disease. *Circulation.* 1997;96(10):3378-83.
 56. Cleary J, Mohr D, Adams MR, **Celermajer DS**, Stocker R. Plasma and LDL levels of major lipophilic antioxidants are similar in patients with advanced atherosclerosis and age-matched controls. *Free Radic Res.* 1997;26(2):175-82.
 57. Donaghue KC, Robinson J, McCredie R, Fung A, Silink M, **Celermajer DS**. Large vessel dysfunction in diabetic adolescents and its relationship to small vessel complications. *J Pediatr Endocrinol Metab.* 1997;10(6):593-8.
 58. Herman SM, Robinson JT, McCredie RJ, Adams MR, Boyer MJ, **Celermajer DS**. Androgen deprivation is associated with enhanced endothelium-dependent dilatation in adult men. *Arterioscler Thromb Vasc Biol.* 1997;17(10):2004-9.

59. McCrohon JA, Walters WA, Robinson JT, McCredie RJ, Turner L, Adams MR, Handelsman DJ, **Celermajer DS**. Arterial reactivity is enhanced in genetic males taking high dose estrogens. *J Am Coll Cardiol*. 1997;29(7):1432-6.
60. Robinson TD, **Celermajer DS**, Bye PT. How to stop ACE-inhibitor-induced cough. *Lancet*. 1997;350(9070):3-4.
61. Sorensen K, Dorup I, **Celermajer DS**. Non invasive assessment of endothelial vasomotor function. In: Bonn GVR, Schwartz CJ, editors. *Vascular Endothelium*. Schaffauer, Stuttgart 1997. p. 373-84.
62. Sorensen KE, Kristensen IB, **Celermajer DS**. Atherosclerosis in the human brachial artery. *J Am Coll Cardiol*. 1997;29(2):318-22.
63. Woo KS, Chook P, Lolin YI, Cheung AS, Chan LT, Sun YY, Sanderson JE, Metreweli C, **Celermajer DS**. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. *Circulation*. 1997;96(8):2542-4.
64. Woo KS, McCrohon JA, Chook P, Adams MR, Robinson JT, McCredie RJ, Lam CW, Feng JZ, **Celermajer DS**. Chinese adults are less susceptible than whites to age-related endothelial dysfunction. *J Am Coll Cardiol*. 1997;30(1):113-8.
65. Woo KS, Robinson JT, Chook P, Adams MR, Yip G, Mai ZJ, Lam CW, Sorensen KE, Deanfield JE, **Celermajer DS**. Differences in the effect of cigarette smoking on endothelial function in chinese and white adults. *Ann Intern Med*. 1997;127(5):372-5.
66. Adams MR, Robinson J, McCredie R, Seale JP, Sorensen KE, Deanfield JE, **Celermajer DS**. Smooth muscle dysfunction occurs independently of impaired endothelium-dependent dilation in adults at risk of atherosclerosis. *J Am Coll Cardiol*. 1998;32(1):123-7.
67. **Celermajer DS**. Noninvasive detection of atherosclerosis. *N Engl J Med*. 1998;339(27):2014-5.
68. **Celermajer DS**. Testing endothelial function using ultrasound. *J Cardiovasc Pharmacol*. 1998;32 Suppl 3:S29-32.
69. **Celermajer DS**. Evidence based Medicine - an old friend or a new foe? . *Asia Pacific Heart J* 1998(7):89.
70. Donaghue KC, Robinson J, McCredie R, Fung A, Silink M, **Celermajer DS**. Macroangiopathy--does it play a role in young people? *Horm Res*. 1998;50 Suppl 1:38-40.
71. Gayagay G, Yu B, Hambly B, Boston T, Hahn A, **Celermajer DS**, Trent RJ. Elite endurance athletes and the ACE I allele--the role of genes in athletic performance. *Hum Genet*. 1998;103(1):48-50.
72. Hornung TS, Bernard EJ, Jaeggi ET, Howman-Giles RB, **Celermajer DS**, Hawker RE. Myocardial perfusion defects and associated systemic ventricular dysfunction in congenitally corrected transposition of the great arteries. *Heart*. 1998;80(4):322-6.
73. Kariappa SM, Assaad NN, Chard RB, Hughes CF, **Celermajer DS**. Congenital heart surgery in adults: an Australian experience of 379 cases. 1998(7):22-5.
74. McCredie RJ, McCrohon JA, Turner L, Griffiths KA, Handelsman DJ, **Celermajer DS**. Vascular reactivity is impaired in genetic females taking high-dose androgens. *J Am Coll Cardiol*. 1998;32(5):1331-5.

75. Parsons S, **Celermajer D**, Savidis E, Miller O, Young I. The effect of inhaled nitric oxide on 6-minute walk distance in patients with pulmonary hypertension. *Chest*. 1998;114(1 Suppl):70S-2S.
76. Pepine CJ, **Celermajer DS**, Drexler H. Vascular health as a therapeutic target in cardiovascular disease (monograph). Office of Continuing Medical Education, University of Florida, ; 1998.
77. Raitakari OT, **Celermajer DS**. Endothelial function of peripheral arteries: a window for presymptomatic detection of atherosclerosis. . *J Cardiac Dis Prevent* 1998;1:2-6.
78. Simons LA, Sullivan D, Simons J, **Celermajer DS**. Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia. *Atherosclerosis*. 1998;137(1):197-203.
79. Tai YF, Saunders JB, **Celermajer DS**. Collateral damage from alcohol abuse: the enormous costs to Australia. *Med J Aust*. 1998;168(1):6-7.
80. Adams MR, **Celermajer DS**. Plasma lipoprotein disorders and endothelial function. In: Barter P, Rye KA editors. *Plasma lipids and their role in disease*. Reading, UK: Harwood Academic Publishers; 1999. p. 191-204.
81. Adams MR, **Celermajer DS**. Detection of presymptomatic atherosclerosis: a current perspective. *Clin Sci (Lond)*. 1999;97(5):615-24.
82. Adams MR, Phu CV, Stocker R, **Celermajer DS**. Lack of antioxidant activity of the antiatherogenic compound L-arginine. *Atherosclerosis*. 1999;146(2):329-35.
83. **Celermajer DS**. Gender at the limits. In: Opie LH, DM Y, editors. *Cardiology at the limits III*. Cape Town Cape Town 1999. p. 47-61.
84. **Celermajer DS**, JE D. Flow mediated dilatation and cardiovascular risk. In: Vallance P, Webb D, editors. *Vascular endothelium in human physiology and pathophysiology*. Reading, UK: Harwood Academic Publishers; 1999. p. 191-202.
85. **Celermajer DS**, Harris PJ. Computed tomography screening for coronary disease. *Med J Aust*. 1999;171(5):232-3.
86. Hornung TS, Bernard EJ, **Celermajer DS**, Jaeggi E, Howman-Giles RB, Chard RB, Hawker RE. Right ventricular dysfunction in congenitally corrected transposition of the great arteries. *Am J Cardiol*. 1999;84(9):1116-9, A10.
87. Kilian JG, Kerr K, Lawrence C, **Celermajer DS**. Myocarditis and cardiomyopathy associated with clozapine. *Lancet*. 1999;354(9193):1841-5.
88. McCrohon JA, Jessup W, Handelsman DJ, **Celermajer DS**. Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1. *Circulation*. 1999;99(17):2317-22.
89. McCrohon JA, Nakhla S, Jessup W, Stanley KK, **Celermajer DS**. Estrogen and progesterone reduce lipid accumulation in human monocyte-derived macrophages: a sex-specific effect. *Circulation*. 1999;100(23):2319-25.
90. McFarlane R, McCredie RJ, Bonney MA, Molyneaux L, Zilkens R, **Celermajer DS**, Yue DK. Angiotensin converting enzyme inhibition and arterial endothelial function in adults with Type 1 diabetes mellitus. *Diabet Med*. 1999;16(1):62-6.

91. Raitakari OT, Adams MR, **Celermajer DS**. Effect of Lp(a) on the early functional and structural changes of atherosclerosis. *Arterioscler Thromb Vasc Biol*. 1999;19(4):990-5.
92. Raitakari OT, Adams MR, McCredie RJ, Griffiths KA, **Celermajer DS**. Arterial endothelial dysfunction related to passive smoking is potentially reversible in healthy young adults. *Ann Intern Med*. 1999;130(7):578-81.
93. Simons LA, von Konigsmark M, Simons J, Stocker R, **Celermajer DS**. Vitamin E ingestion does not improve arterial endothelial dysfunction in older adults. *Atherosclerosis*. 1999;143(1):193-9.
94. Tan KL, Robinson TD, **Celermajer DS**, Hughes CF, Young IH. Intermittent hypoxaemia without orthodeoxia due to right-to-left shunting related to an elongated aorta. *Respirology*. 1999;4(3):291-3.
95. Wilson SH, **Celermajer DS**, Nakagomi A, Wyndham RN, Janu MR, Ben Freedman S. Vascular risk factors correlate to the extent as well as the severity of coronary atherosclerosis. *Coron Artery Dis*. 1999;10(7):449-53.
96. Woo KS, Chook P, Lolin YI, Sanderson JE, Metreweli C, **Celermajer DS**. Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. *J Am Coll Cardiol*. 1999;34(7):2002-6.
97. Woo KS, Chook P, Raitakari OT, McQuillan B, Feng JZ, **Celermajer DS**. Westernization of Chinese adults and increased subclinical atherosclerosis. *Arterioscler Thromb Vasc Biol*. 1999;19(10):2487-93.
98. **Celermajer D**, Vita JA. Vascular dysfunction and its contribution to atherogenesis. In: Rt Dean DK, editor. *Atherosclerosis: Gene Expression, Cell Interactions, and Oxidation*. Oxford: Oxford University Press; 2000. p. 88-111.
99. Graham TP, Jr., Bernard YD, Mellen BG, **Celermajer D**, Baumgartner H, Cetta F, Connolly HM, Davidson WR, Dellborg M, Foster E, Gersony WM, Gessner IH, Hurwitz RA, Kaemmerer H, Kugler JD, Murphy DJ, Noonan JA, Morris C, Perloff JK, Sanders SP, Sutherland JL. Long-term outcome in congenitally corrected transposition of the great arteries: a multi-institutional study. *J Am Coll Cardiol*. 2000;36(1):255-61.
100. Lau AK, Witting PK, Chaufour X, **Celermajer DS**, Pettersson K, Stocker R. Protective effects of probucol in two animal models of atherosclerosis. *Redox Rep*. 2000;5(2-3):116-8.
101. McCrohon JA, Death AK, Nakhla S, Jessup W, Handelsman DJ, Stanley KK, **Celermajer DS**. Androgen receptor expression is greater in macrophages from male than from female donors. A sex difference with implications for atherogenesis. *Circulation*. 2000;101(3):224-6.
102. McCrohon JA, Woo KS, **Celermajer DS**. A comparison of endothelial function in Caucasian and Chinese women before and after the menopause. *Maturitas*. 2000;35(1):31-7.
103. Millane T, Bernard EJ, Jaeggi E, Howman-Giles RB, Uren RF, Cartmill TB, Hawker RE, **Celermajer DS**. Role of ischemia and infarction in late right ventricular dysfunction after atrial repair of transposition of the great arteries. *J Am Coll Cardiol*. 2000;35(6):1661-8.
104. Miller OI, Tang SF, Keech A, Pigott NB, Beller E, **Celermajer DS**. Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomised

- double-blind study. *Lancet*. 2000;356(9240):1464-9.
105. Premawardhana U, **Celermajer DS**. Advances in echocardiography. *Aust N Z J Med*. 2000;30(3):360-6.
 106. Premawardhana U, Hoskin M, **Celermajer DS**. Transvenous echo Doppler in baboons: a new window to the cardiovascular system. *Clin Sci (Lond)*. 2000;99(2):141-7.
 107. Raitakari OT, Adams MR, McCredie RJ, Griffiths KA, Stocker R, **Celermajer DS**. Oral vitamin C and endothelial function in smokers: short-term improvement, but no sustained beneficial effect. *J Am Coll Cardiol*. 2000;35(6):1616-21.
 108. Raitakari OT, **Celermajer DS**. Flow-mediated dilatation. *Br J Clin Pharmacol*. 2000;50(5):397-404.
 109. Raitakari OT, **Celermajer DS**. Testing for endothelial dysfunction. *Ann Med*. 2000;32(5):293-304.
 110. Raitakari OT, Lai N, Griffiths K, McCredie R, Sullivan D, **Celermajer DS**. Enhanced peripheral vasodilation in humans after a fatty meal. *J Am Coll Cardiol*. 2000;36(2):417-22.
 111. Raitakari OT, McCredie RJ, Witting P, Griffiths KA, Letters J, Sullivan D, Stocker R, **Celermajer DS**. Coenzyme Q improves LDL resistance to ex vivo oxidation but does not enhance endothelial function in hypercholesterolemic young adults. *Free Radic Biol Med*. 2000;28(7):1100-5.
 112. Rasko J, **Celermajer D**. Gene therapy for vascular diseases. In: Rt Dean DK, editor. *Atherosclerosis: Gene Expression, Cell Interactions, and Oxidation*. Oxford: Oxford University Press; 2000. p. 112-36.
 113. Simons LA, von Konigsmark M, Simons J, **Celermajer DS**. Phytoestrogens do not influence lipoprotein levels or endothelial function in healthy, postmenopausal women. *Am J Cardiol*. 2000;85(11):1297-301.
 114. Woo KS, Chook P, Leong HC, Huang XS, **Celermajer DS**. The impact of heavy passive smoking on arterial endothelial function in modernized Chinese. *J Am Coll Cardiol*. 2000;36(4):1228-32.
 115. Woo KS, Sanderson JE, Sun YY, Chook P, Cheung AS, Chan LT, Metreweli C, Lolin YI, **Celermajer DS**. Hyperhomocystinemia is a risk factor for arterial endothelial dysfunction in humans. *Circulation*. 2000;101(12):E116.
 116. **Celermajer DS**. Evidence-based medicine: how good is the evidence? *Med J Aust*. 2001;174(6):293-5.
 117. Dzau VJ, Bernstein K, **Celermajer D**, Cohen J, Dahlof B, Deanfield J, Diez J, Drexler H, Ferrari R, van Gilst W, Hansson L, Hornig B, Husain A, Johnston C, Lazar H, Lonn E, Luscher T, Mancini J, Mimran A, Pepine C, Rabelink T, Remme W, Ruilope L, Ruzicka M, Schunkert H, Swedberg K, Unger T, Vaughan D, Weber M, Working Group on Tissue Angiotensin-converting enzyme ISoCP. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. *Am J Cardiol*. 2001;88(9A):1L-20L.
 118. Jarvisalo MJ, Jartti L, Nanto-Salonen K, Irfjala K, Ronnema T, Hartiala JJ, **Celermajer DS**, Raitakari OT. Increased aortic intima-media thickness: a marker of preclinical

- atherosclerosis in high-risk children. *Circulation*. 2001;104(24):2943-7.
119. Langenfeld MR, Nakhla S, Death AK, Jessup W, **Celermajer DS**. Endothelin-1 plus oxidized low-density lipoprotein, but neither alone, increase human monocyte adhesion to endothelial cells. *Clin Sci (Lond)*. 2001;101(6):731-8.
 120. Ly LP, Jimenez M, Zhuang TN, **Celermajer DS**, Conway AJ, Handelsman DJ. A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. *J Clin Endocrinol Metab*. 2001;86(9):4078-88.
 121. Ng MK, Jessup W, **Celermajer DS**. Sex-related differences in the regulation of macrophage cholesterol metabolism. *Curr Opin Lipidol*. 2001;12(5):505-10.
 122. Premawardhana U, Adams MR, Birrell A, Yue DK, **Celermajer DS**. Cardiovascular structure and function in baboons with Type 1 diabetes – a transvenous ultrasound study. *J Diabetes Complications*. 2001;15(4):174-80.
 123. Raitakari OT, Seale JP, **Celermajer DS**. Impaired vascular responses to nitroglycerin in subjects with coronary atherosclerosis. *Am J Cardiol*. 2001;87(2):217-9, A8.
 124. Sader MA, Griffiths KA, McCredie RJ, Handelsman DJ, **Celermajer DS**. Androgenic anabolic steroids and arterial structure and function in male bodybuilders. *J Am Coll Cardiol*. 2001;37(1):224-30.
 125. Sader MA, McCredie RJ, Griffiths KA, Wishart SM, Handelsman DJ, **Celermajer DS**. Oestradiol improves arterial endothelial function in healthy men receiving testosterone. *Clin Endocrinol (Oxf)*. 2001;54(2):175-81.
 126. Woo J, Woo KS, Leung SS, Chook P, Liu B, Ip R, Ho SC, Chan SW, Feng JZ, **Celermajer DS**. The Mediterranean score of dietary habits in Chinese populations in four different geographical areas. *Eur J Clin Nutr*. 2001;55(3):215-20.
 127. Woo KS, Chook P, Chan WB, So WY, Cockram CS, **Celermajer DS**. Type 1 diabetes and arterial dysfunction in asymptomatic Chinese adults. *Diabetes Care*. 2001;24(1):173.
 128. **Celermajer D**. Understanding the pathophysiology of the arterial wall: which method should we choose? *European Heart Journal Supplements*. 2002;4(suppl F):F24-F8.
 129. **Celermajer DS**, Greaves K. Survivors of coarctation repair: fixed but not cured. *Heart*. 2002;88(2):113-4.
 130. Corretti MC, Anderson TJ, Benjamin EJ, **Celermajer D**, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R, International Brachial Artery Reactivity Task F. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. *J Am Coll Cardiol*. 2002;39(2):257-65.
 131. Death AK, Nakhla S, McGrath KC, Martell S, Yue DK, Jessup W, **Celermajer DS**. Nitroglycerin upregulates matrix metalloproteinase expression by human macrophages. *J Am Coll Cardiol*. 2002;39(12):1943-50.
 132. Dzau VJ, Bernstein K, **Celermajer D**, Cohen J, Dahlof B, Deanfield J, Diez J, Drexler H, Ferrari R, Van Gilst W, Hansson L, Hornig B, Husain A, Johnston C, Lazar H, Lonn E,

- Luscher T, Mancini J, Mimran A, Pepine C, Rabelink T, Remme W, Ruilope L, Ruzicka M, Schunkert H, Swedberg K, Unger T, Vaughan D, Weber M. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. *Cardiovasc Drugs Ther.* 2002;16(2):149-60.
133. Kilian JG, Keech A, Adams MR, **Celermajer DS**. Coronary collateralization: determinants of adequate distal vessel filling after arterial occlusion. *Coron Artery Dis.* 2002;13(3):155-9.
 134. Ng MK, Liu PY, Williams AJ, Nakhla S, Ly LP, Handelsman DJ, **Celermajer DS**. Prospective study of effect of androgens on serum inflammatory markers in men. *Arterioscler Thromb Vasc Biol.* 2002;22(7):1136-41.
 135. Sader MA, **Celermajer DS**. Endothelial function, vascular reactivity and gender differences in the cardiovascular system. *Cardiovasc Res.* 2002;53(3):597-604.
 136. Sader MA, Miller LA, Caine D, McCredie RJ, Corr MJ, Robertson M, Watson JD, **Celermajer DS**. Neuropsychological and psychiatric outcomes following coronary surgery or angioplasty: a comparative study. *Heart Lung Circ.* 2002;11(2):95-101.
 137. Wilson SH, Best PJ, Edwards WD, Holmes DR, Jr., Carlson PJ, **Celermajer DS**, Lerman A. Nuclear factor-kappaB immunoreactivity is present in human coronary plaque and enhanced in patients with unstable angina pectoris. *Atherosclerosis.* 2002;160(1):147-53.
 138. Woo KS, Chook P, Chan LL, Cheung AS, Fung WH, Qiao M, Lolin YI, Thomas GN, Sanderson JE, Metreweli C, **Celermajer DS**. Long-term improvement in homocysteine levels and arterial endothelial function after 1-year folic acid supplementation. *Am J Med.* 2002;112(7):535-9.
 139. **Celermajer D**. Lessons from history for the younger cardiologist. *Heart Lung Circ.* 2003;12 Suppl 1:S29-31.
 140. **Celermajer D**, Deanfield J. Congenital heart disease in adolescents and adults. (CHD in Adolescence). In: Anderson Rh, M. T, M. R, editors. *Paediatric Cardiology.* 2. London: Churchill Livingstone; 2003. p. 1893-925.
 141. **Celermajer D**, Deanfield J. Diseases of the tricuspid valve. In: Anderson Rh, M. T, M. R, editors. *Paediatric Cardiology.* 2. London: Churchill Livingstone; 2003. p. 1111-33.
 142. **Celermajer DS**. Statins, skin, and the search for a test of endothelial function. *J Am Coll Cardiol.* 2003;42(1):78-80.
 143. **Celermajer DS**. Clinical trials: Evidence and unanswered questions--hypertension. *Cerebrovasc Dis.* 2003;16 Suppl 3:18-24.
 144. Greaves K, Bye P, Parker G, **Celermajer DS**. Prevalence of haemoptysis in adults with pulmonary atresia and ventricular septal defect, and the role of mammary artery collateral vessels. *Heart.* 2003;89(8):937-8.
 145. Greaves K, Mou D, Patel A, **Celermajer DS**. Clinical criteria and the appropriate use of transthoracic echocardiography for the exclusion of infective endocarditis. *Heart.* 2003;89(3):273-5.
 146. Griffiths KA, Sader MA, Skilton MR, Harmer JA, **Celermajer DS**. Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease. *J Am Coll Cardiol.* 2003;42(4):698-

704.

147. Langenfeld MR, Simmons LA, McCrohon JA, Raitakari OT, Lattimore JD, Hennessy A, **Celermajer DS**. Nitric oxide does not mediate the vasodilation of early human pregnancy. *Heart Lung Circ*. 2003;12(3):142-8.
148. Lattimore JD, **Celermajer DS**, Wilcox I. Obstructive sleep apnea and cardiovascular disease. *J Am Coll Cardiol*. 2003;41(9):1429-37.
149. Lau AK, Leichtweis SB, Hume P, Mashima R, Hou JY, Chaufour X, Wilkinson B, Hunt NH, **Celermajer DS**, Stocker R. Probucol promotes functional reendothelialization in balloon-injured rabbit aortas. *Circulation*. 2003;107(15):2031-6.
150. Liu PY, Wishart SM, **Celermajer DS**, Jimenez M, Pierro ID, Conway AJ, Handelsman DJ. Do reproductive hormones modify insulin sensitivity and metabolism in older men? A randomized, placebo-controlled clinical trial of recombinant human chorionic gonadotropin. *Eur J Endocrinol*. 2003;148(1):55-66.
151. Ng MK, Nakhla S, Baoutina A, Jessup W, Handelsman DJ, **Celermajer DS**. Dehydroepiandrosterone, an adrenal androgen, increases human foam cell formation: a potentially pro-atherogenic effect. *J Am Coll Cardiol*. 2003;42(11):1967-74.
152. Ng MK, Quinn CM, McCrohon JA, Nakhla S, Jessup W, Handelsman DJ, **Celermajer DS**, Death AK. Androgens up-regulate atherosclerosis-related genes in macrophages from males but not females: molecular insights into gender differences in atherosclerosis. *J Am Coll Cardiol*. 2003;42(7):1306-13.
153. Puranik R, **Celermajer DS**. Smoking and endothelial function. *Prog Cardiovasc Dis*. 2003;45(6):443-58.
154. Sader MA, Griffiths KA, Skilton MR, Wishart SM, Handelsman DJ, **Celermajer DS**. Physiological testosterone replacement and arterial endothelial function in men. *Clin Endocrinol (Oxf)*. 2003;59(1):62-7.
155. Sheil ML, Cartmill TB, Nunn GR, Sholler GF, Raitakari OT, **Celermajer DS**. Contrast echocardiography: potential for the in-vivo study of pediatric myocardial preservation. *Ann Thorac Surg*. 2003;75(5):1542-8; discussion 9.
156. Death AK, McGrath KC, Sader MA, Nakhla S, Jessup W, Handelsman DJ, **Celermajer DS**. Dihydrotestosterone promotes vascular cell adhesion molecule-1 expression in male human endothelial cells via a nuclear factor-kappaB-dependent pathway. *Endocrinology*. 2004;145(4):1889-97.
157. Greaves K, Puranik R, O'Leary JJ, **Celermajer DS**. Myocardial tissue velocities in the normal left and right ventricle: relationships and predictors. *Heart Lung Circ*. 2004;13(4):367-73.
158. Kerridge I, Stewart G, Raper M, **Celermajer D**, Willcock S. "The Future of Medicine" - What is wrong with medicine today? and Where is the future of medicine? 2004.
159. Ng MK, **Celermajer DS**. Glucocorticoid treatment and cardiovascular disease. *Heart*. 2004;90(8):829-30.
160. Sullivan DR, **Celermajer DS**, Le Couteur DG, Lam CW. The vascular implications of post-prandial lipoprotein metabolism. *Clin Biochem Rev*. 2004;25(1):19-30.

161. Thomas GN, Chook P, Qiao M, Huang XS, Leong HC, **Celermajer DS**, Woo KS. Deleterious impact of "high normal" glucose levels and other metabolic syndrome components on arterial endothelial function and intima-media thickness in apparently healthy Chinese subjects: the CATHAY study. *Arterioscler Thromb Vasc Biol.* 2004;24(4):739-43.
162. Woo KS, Chook P, Yu CW, Sung RY, Qiao M, Leung SS, Lam CW, Metreweli C, **Celermajer DS**. Effects of diet and exercise on obesity-related vascular dysfunction in children. *Circulation.* 2004;109(16):1981-6.
163. Woo KS, Chook P, Yu CW, Sung RY, Qiao M, Leung SS, Lam CW, Metreweli C, **Celermajer DS**. Overweight in children is associated with arterial endothelial dysfunction and intima-media thickening. *Int J Obes Relat Metab Disord.* 2004;28(7):852-7.
164. Woodman RJ, **Celermajer DE**, Thompson PL, Hung J. Folic acid does not improve endothelial function in healthy hyperhomocysteinaemic subjects. *Clin Sci (Lond).* 2004;106(4):353-8.
165. **Celermajer DS**. Brachial artery FMD with 5-minute distal cuff occlusion--a useful pathophysiological test after all! *J Appl Physiol (1985).* 2005;99(4):1619.
166. **Celermajer DS**. Primary and a half prevention: can we identify asymptomatic subjects with high vascular risk? *J Am Coll Cardiol.* 2005;45(12):1994-6.
167. Chow CK, Amos D, **Celermajer DS**. Cerebrovascular events in young adults after surgical repair of tetralogy of Fallot. *Cardiol Young.* 2005;15(2):130-2.
168. Chow CK, Mou D, Patel A, **Celermajer DS**. The role of the 12-lead ECG as a screening test for cardiac source of embolus. *Heart Lung Circ.* 2005;14(4):242-4.
169. Joshua AM, **Celermajer DS**, Stockler MR. Beauty is in the eye of the examiner: reaching agreement about physical signs and their value. *Intern Med J.* 2005;35(3):178-87.
170. Keech AC, Grieve SM, Patel A, Griffiths K, Skilton M, Watts GF, Marwick TH, Groshens M, **Celermajer DS**. Urinary albumin levels in the normal range determine arterial wall thickness in adults with Type 2 diabetes: a FIELD substudy. *Diabet Med.* 2005;22(11):1558-65.
171. Kilian JG, **Celermajer DS**, Adams MR. Safety of coronary angioplasty to chronic total occlusions. *Int J Cardiol.* 2005;103(3):256-8.
172. Kilian JG, Nakhla S, Griffith K, Harmer J, Skilton M, **Celermajer DS**. Reperfusion injury in the human forearm is mild and not attenuated by short-term ischaemic preconditioning. *Clin Exp Pharmacol Physiol.* 2005;32(1-2):86-90.
173. Kilian JG, Nakhla S, Sieveking DP, **Celermajer DS**. Adenosine prevents neutrophil adhesion to human endothelial cells after hypoxia/reoxygenation. *Int J Cardiol.* 2005;105(3):322-6.
174. Kwok T, Chook P, Tam L, Qiao M, Woo JL, **Celermajer DS**, Woo KS. Vascular dysfunction in Chinese vegetarians: an apparent paradox? *J Am Coll Cardiol.* 2005;46(10):1957-8.
175. Lattimore JD, Wilcox I, Nakhla S, Langenfeld M, Jessup W, **Celermajer DS**. Repetitive hypoxia increases lipid loading in human macrophages-a potentially atherogenic effect. *Atherosclerosis.* 2005;179(2):255-9.
176. Lundman P, Keech AC, Griffiths K, Pillai A, **Celermajer DS**. New carotid plaque formation

- is very common in adult patients with Type 2 diabetes mellitus. *Diabet Med.* 2005;22(3):355-6.
177. Maple-Brown LJ, Piers LS, O'Rourke MF, **Celermajer DS**, O'Dea K. Central obesity is associated with reduced peripheral wave reflection in Indigenous Australians irrespective of diabetes status. *J Hypertens.* 2005;23(7):1403-7.
 178. Sader MA, McGrath KC, Hill MD, Bradstock KF, Jimenez M, Handelsman DJ, **Celermajer DS**, Death AK. Androgen receptor gene expression in leucocytes is hormonally regulated: implications for gender differences in disease pathogenesis. *Clin Endocrinol (Oxf).* 2005;62(1):56-63.
 179. Sheil ML, Luxford C, Davies MJ, Peat JK, Nunn G, **Celermajer DS**. Protein oxidation injury occurs during pediatric cardiopulmonary bypass. *J Thorac Cardiovasc Surg.* 2005;130(4):1054-61.
 180. Sieveking DP, Woo KS, Fung KP, Lundman P, Nakhla S, **Celermajer DS**. Chinese herbs Danshen and Gegen modulate key early atherogenic events in vitro. *Int J Cardiol.* 2005;105(1):40-5.
 181. Skilton MR, Evans N, Griffiths KA, Harmer JA, **Celermajer DS**. Aortic wall thickness in newborns with intrauterine growth restriction. *Lancet.* 2005;365(9469):1484-6.
 182. Skilton MR, Lai NT, Griffiths KA, Molyneaux LM, Yue DK, Sullivan DR, **Celermajer DS**. Meal-related increases in vascular reactivity are impaired in older and diabetic adults: insights into roles of aging and insulin in vascular flow. *Am J Physiol Heart Circ Physiol.* 2005;288(3):H1404-10.
 183. Skilton MR, Nakhla S, Sieveking DP, Caterson ID, **Celermajer DS**. Pathophysiological levels of the obesity related peptides resistin and ghrelin increase adhesion molecule expression on human vascular endothelial cells. *Clin Exp Pharmacol Physiol.* 2005;32(10):839-44.
 184. Thanyasiri P, **Celermajer DS**, Adams MR. Endothelial dysfunction occurs in peripheral circulation patients with acute and stable coronary artery disease. *Am J Physiol Heart Circ Physiol.* 2005;289(2):H513-7.
 185. **Celermajer DS**, Ayer JG. Childhood risk factors for adult cardiovascular disease and primary prevention in childhood. *Heart.* 2006;92(11):1701-6.
 186. Chow CK, Raju PK, Raju R, Reddy KS, Cardona M, **Celermajer DS**, Neal BC. The prevalence and management of diabetes in rural India. *Diabetes Care.* 2006;29(7):1717-8.
 187. Kotlyar E, Sy R, Keogh AM, Kermeen F, Macdonald PS, Hayward CS, McNeil KD, **Celermajer DS**. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease. *Cardiol Young.* 2006;16(3):268-74.
 188. Lattimore JL, Wilcox I, Skilton M, Langenfeld M, **Celermajer DS**. Treatment of obstructive sleep apnoea leads to improved microvascular endothelial function in the systemic circulation. *Thorax.* 2006;61(6):491-5.
 189. Lau AK, Chaufour X, McLachlan C, Leichtweis SB, **Celermajer DS**, Sullivan C, Stocker R. Intimal thickening after arterial balloon injury is increased by intermittent repetitive hypoxia, but intermittent repetitive hyperoxia is not protective. *Atherosclerosis.* 2006;185(2):254-63.

190. Nicholls SJ, Lundman P, Harmer JA, Cutri B, Griffiths KA, Rye KA, Barter PJ, **Celermajer DS**. Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function. *J Am Coll Cardiol*. 2006;48(4):715-20.
191. Ou P, **Celermajer DS**, Stos B, Marijon E, Vouhe P, Brunelle F, Bonnet D, Sidi D. Images in cardiovascular medicine. Definitive diagnosis of obstructed total anomalous pulmonary venous drainage in a critically ill newborn with high-resolution computed tomography. *Circulation*. 2006;114(25):e646-7.
192. Ou P, Mousseaux E, **Celermajer DS**, Pedroni E, Vouhe P, Sidi D, Bonnet D. Aortic arch shape deformation after coarctation surgery: effect on blood pressure response. *J Thorac Cardiovasc Surg*. 2006;132(5):1105-11.
193. Patel S, **Celermajer DS**. Assessment of vascular disease using arterial flow mediated dilatation. *Pharmacol Rep*. 2006;58 Suppl:3-7.
194. Skilton MR, **Celermajer DS**. The effects of obesity-related peptides on the vasculature. *Curr Vasc Pharmacol*. 2006;4(1):79-85.
195. Skilton MR, **Celermajer DS**. Endothelial dysfunction and arterial abnormalities in childhood obesity. *Int J Obes (Lond)*. 2006;30(7):1041-9.
196. Skilton MR, Gosby AK, Wu BJ, Ho LM, Stocker R, Caterson ID, **Celermajer DS**. Maternal undernutrition reduces aortic wall thickness and elastin content in offspring rats without altering endothelial function. *Clin Sci (Lond)*. 2006;111(4):281-7.
197. Tanous D, Brasen JH, Choy K, Wu BJ, Kathir K, Lau A, **Celermajer DS**, Stocker R. Probucol inhibits in-stent thrombosis and neointimal hyperplasia by promoting re-endothelialization. *Atherosclerosis*. 2006;189(2):342-9.
198. Thanyasiri P, **Celermajer DS**, Adams MR. Predictors of long-term outcome following percutaneous coronary intervention in patients with type 2 diabetes mellitus. *Coron Artery Dis*. 2006;17(2):131-8.
199. Brand-Miller J, Dickinson S, Barclay A, **Celermajer D**. The glycemic index and cardiovascular disease risk. *Curr Atheroscler Rep*. 2007;9(6):479-85.
200. **Celermajer DS**. Protecting children from passive smoking. *Circulation*. 2007;115(25):3143-4.
201. Chandrasegaram MD, **Celermajer DS**, Wilson MK. Apical ballooning syndrome complicated by acute severe mitral regurgitation with left ventricular outflow obstruction--case report. *J Cardiothorac Surg*. 2007;2:14.
202. Chow C, Cardona M, Raju PK, Iyengar S, Sukumar A, Raju R, Colman S, Madhav P, Raju R, Reddy KS, **Celermajer D**, Neal B. Cardiovascular disease and risk factors among 345 adults in rural India--the Andhra Pradesh Rural Health Initiative. *Int J Cardiol*. 2007;116(2):180-5.
203. Levy M, Maurey C, **Celermajer DS**, Vouhe PR, Danel C, Bonnet D, Israel-Biet D. Impaired apoptosis of pulmonary endothelial cells is associated with intimal proliferation and irreversibility of pulmonary hypertension in congenital heart disease. *J Am Coll Cardiol*. 2007;49(7):803-10.
204. Levy M, Rasky O, Vouhe PR, **Celermajer DS**, Bonnet D, Israel-Biet D. [Apoptotic

- deregulation of endothelial cells and intimal proliferation in pulmonary hypertension of congenital heart disease]. *Arch Mal Coeur Vaiss.* 2007;100(5):365-72.
205. Maple-Brown L, Cunningham J, **Celermajer DS**, O'Dea K. Increased carotid intima-media thickness in remote and urban Indigenous Australians: impact of diabetes and components of the metabolic syndrome. *Clin Endocrinol (Oxf).* 2007;66(3):419-25.
 206. Maple-Brown LJ, Piers LS, O'Rourke MF, **Celermajer DS**, O'Dea K. Increased arterial stiffness in remote Indigenous Australians with high risk of cardiovascular disease. *J Hypertens.* 2007;25(3):585-91.
 207. Marijon E, Ou P, **Celermajer DS**, Ferreira B, Mocumbi AO, Jani D, Paquet C, Jacob S, Sidi D, Jouven X. Prevalence of rheumatic heart disease detected by echocardiographic screening. *N Engl J Med.* 2007;357(5):470-6.
 208. Marijon E, Trinquart L, Jani D, Jourdir H, Garbarz E, Mocumbi AO, **Celermajer DS**, Ferreira B. Coronary heart disease and associated risk factors in sub-Saharan Africans. *J Hum Hypertens.* 2007;21(5):411-4.
 209. Ou P, **Celermajer DS**, Agnoletti G, Brunelle F, Vouhe P, Sidi D, Bonnet D. Images in cardiovascular medicine. Definitive diagnosis of pulmonary artery sling in a critically ill infant with high-resolution computed tomography. *Circulation.* 2007;115(15):e398-9.
 210. Ou P, **Celermajer DS**, Calcagni G, Brunelle F, Bonnet D, Sidi D. Three-dimensional CT scanning: a new diagnostic modality in congenital heart disease. *Heart.* 2007;93(8):908-13.
 211. Ou P, **Celermajer DS**, Mousseaux E, Giron A, Aggoun Y, Szezepanski I, Sidi D, Bonnet D. Vascular remodeling after "successful" repair of coarctation: impact of aortic arch geometry. *J Am Coll Cardiol.* 2007;49(8):883-90.
 212. Patel S, Harmer JA, Loughnan G, Skilton MR, Steinbeck K, **Celermajer DS**. Characteristics of cardiac and vascular structure and function in Prader-Willi syndrome. *Clin Endocrinol (Oxf).* 2007;66(6):771-7.
 213. Proudman SM, Stevens WM, Sahhar J, **Celermajer D**. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. *Intern Med J.* 2007;37(7):485-94.
 214. Puranik R, Greaves K, Hawker RE, Pressley LA, Robinson PJ, **Celermajer DS**. Abnormal right ventricular tissue velocities after repair of congenital heart disease—implications for late outcomes. *Heart Lung Circ.* 2007;16(4):295-9.
 215. Thanyasiri P, Kathir K, **Celermajer DS**, Adams MR. Endothelial dysfunction and restenosis following percutaneous coronary intervention. *Int J Cardiol.* 2007;119(3):362-7.
 216. Yeo TW, Lampah DA, Gitawati R, Tjitra E, Kenangalem E, McNeil YR, Darcy CJ, Granger DL, Weinberg JB, Lopansri BK, Price RN, Duffull SB, **Celermajer DS**, Anstey NM. Impaired nitric oxide bioavailability and L-arginine reversible endothelial dysfunction in adults with falciparum malaria. *J Exp Med.* 2007;204(11):2693-704.
 217. Agnoletti G, Ou P, **Celermajer DS**, Boudjemline Y, Marini D, Bonnet D, Aggoun Y. Acute angulation of the aortic arch predisposes a patient to ascending aortic dilatation and aortic regurgitation late after the arterial switch operation for transposition of the great arteries. *J Thorac Cardiovasc Surg.* 2008;135(3):568-72.

218. Ayer JG, Almafragy HS, Patel AA, Hellyer RL, **Celermajer DS**. Body mass index is an independent determinant of left atrial size. *Heart Lung Circ*. 2008;17(1):19-24.
219. Brooks BA, Franjic B, Ban CR, Swaraj K, Yue DK, **Celermajer DS**, Twigg SM. Diastolic dysfunction and abnormalities of the microcirculation in type 2 diabetes. *Diabetes Obes Metab*. 2008;10(9):739-46.
220. **Celermajer DS**. Reliable endothelial function testing: at our fingertips? *Circulation*. 2008;117(19):2428-30.
221. **Celermajer DS**, Marwick T. Echocardiographic and right heart catheterization techniques in patients with pulmonary arterial hypertension. *Int J Cardiol*. 2008;125(3):294-303.
222. **Celermajer DS**, Ng MK. Where there's smoke. *J Am Coll Cardiol*. 2008;51(18):1772-4.
223. Chow CK, McQuillan B, Raju PK, Iyengar S, Raju R, Harmer JA, Neal BC, **Celermajer DS**. Greater adverse effects of cholesterol and diabetes on carotid intima-media thickness in South Asian Indians: comparison of risk factor-IMT associations in two population-based surveys. *Atherosclerosis*. 2008;199(1):116-22.
224. Chow CK, Naidu S, Raju K, Raju R, Joshi R, Sullivan D, **Celermajer DS**, Neal BC. Significant lipid, adiposity and metabolic abnormalities amongst 4535 Indians from a developing region of rural Andhra Pradesh. *Atherosclerosis*. 2008;196(2):943-52.
225. Kilian JG, Thanyasiri P, **Celermajer DS**, Adams MR. Saphenous vein grafts display poor endothelium-dependent and endothelium-independent dilation—implications for the pathogenesis of vein graft atherosclerosis. *Heart Lung Circ*. 2008;17(2):96-9.
226. Lattimore JD, Wilcox I, Adams MR, Kilian JG, **Celermajer DS**. Treatment of obstructive sleep apnoea leads to enhanced pulmonary vascular nitric oxide release. *Int J Cardiol*. 2008;126(2):229-33.
227. Marijon E, Ou P, **Celermajer DS**, Ferreira B, Mocumbi AO, Sidi D, Jouven X. Echocardiographic screening for rheumatic heart disease. *Bull World Health Organ*. 2008;86(2):84.
228. McGrady M, Thanyasiri P, Bailey BP, **Celermajer DS**, Adams MR. Determinants of coronary arterial flow-mediated dilatation following percutaneous coronary intervention. *Catheter Cardiovasc Interv*. 2008;71(3):327-32.
229. Ou P, **Celermajer DS**, Jolivet O, Buyens F, Herment A, Sidi D, Bonnet D, Mousseaux E. Increased central aortic stiffness and left ventricular mass in normotensive young subjects after successful coarctation repair. *Am Heart J*. 2008;155(1):187-93.
230. Ou P, **Celermajer DS**, Marini D, Agnoletti G, Vouhe P, Brunelle F, Le Quan Sang KH, Thalabard JC, Sidi D, Bonnet D. Safety and accuracy of 64-slice computed tomography coronary angiography in children after the arterial switch operation for transposition of the great arteries. *JACC Cardiovasc Imaging*. 2008;1(3):331-9.
231. Ou P, **Celermajer DS**, Raisy O, Jolivet O, Buyens F, Herment A, Sidi D, Bonnet D, Mousseaux E. Angular (Gothic) aortic arch leads to enhanced systolic wave reflection, central aortic stiffness, and increased left ventricular mass late after aortic coarctation repair: evaluation with magnetic resonance flow mapping. *J Thorac Cardiovasc Surg*. 2008;135(1):62-8.

232. Patel S, **Celermajer DS**, Bao S. Atherosclerosis-underlying inflammatory mechanisms and clinical implications. *Int J Biochem Cell Biol.* 2008;40(4):576-80.
233. Puranik R, Bao S, Nobecourt E, Nicholls SJ, Dusting GJ, Barter PJ, **Celermajer DS**, Rye KA. Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo. *Atherosclerosis.* 2008;196(1):240-7.
234. Sieveking DP, Buckle A, **Celermajer DS**, Ng MK. Strikingly different angiogenic properties of endothelial progenitor cell subpopulations: insights from a novel human angiogenesis assay. *J Am Coll Cardiol.* 2008;51(6):660-8.
235. Skilton MR, Sieveking DP, Harmer JA, Franklin J, Loughnan G, Nakhla S, Sullivan DR, Caterson ID, **Celermajer DS**. The effects of obesity and non-pharmacological weight loss on vascular and ventricular function and structure. *Diabetes Obes Metab.* 2008;10(10):874-84.
236. Thomas GN, Chook P, Yip TW, Kwong SK, Chan TY, Qiao M, Huang XS, Guo DS, Feng JZ, Chan SW, Leong HC, **Celermajer DS**, Woo KS. Smoking without exception adversely affects vascular structure and function in apparently healthy Chinese: implications in global atherosclerosis prevention. *Int J Cardiol.* 2008;128(2):172-7.
237. Yeo TW, Lampah DA, Gitawati R, Tjitra E, Kenangalem E, Granger DL, Weinberg JB, Lopansri BK, Price RN, **Celermajer DS**, Duffull SB, Anstey NM. Safety profile of L-arginine infusion in moderately severe falciparum malaria. *PLoS One.* 2008;3(6):e2347.
238. Yeo TW, Lampah DA, Gitawati R, Tjitra E, Kenangalem E, McNeil YR, Darcy CJ, Granger DL, Weinberg JB, Lopansri BK, Price RN, Duffull SB, **Celermajer DS**, Anstey NM. Recovery of endothelial function in severe falciparum malaria: relationship with improvement in plasma L-arginine and blood lactate concentrations. *J Infect Dis.* 2008;198(4):602-8.
239. Yeo TW, Lampah DA, Gitawati R, Tjitra E, Kenangalem E, Piera K, Price RN, Duffull SB, **Celermajer DS**, Anstey NM. Angiopietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria. *Proc Natl Acad Sci U S A.* 2008;105(44):17097-102.
240. Ayer JG, Harmer JA, Nakhla S, Xuan W, Ng MK, Raitakari OT, Marks GB, **Celermajer DS**. HDL-cholesterol, blood pressure, and asymmetric dimethylarginine are significantly associated with arterial wall thickness in children. *Arterioscler Thromb Vasc Biol.* 2009;29(6):943-9.
241. Ayer JG, Harmer JA, Xuan W, Toelle B, Webb K, Almqvist C, Marks GB, **Celermajer DS**. Dietary supplementation with n-3 polyunsaturated fatty acids in early childhood: effects on blood pressure and arterial structure and function at age 8 y. *Am J Clin Nutr.* 2009;90(2):438-46.
242. **Celermajer DS**. Wait for weight or "waste" the waist: the benefits of early intervention in childhood obesity. *J Am Coll Cardiol.* 2009;54(25):2407-8.
243. **Celermajer DS**, Chow CK. Concerning an oversight. *Atherosclerosis.* 2009;204(2):352.
244. Chow CK, Joshi R, **Celermajer DS**, Patel A, Neal BC. Recalibration of a Framingham risk equation for a rural population in India. *J Epidemiol Community Health.* 2009;63(5):379-85.
245. Davis JS, Yeo TW, Thomas JH, McMillan M, Darcy CJ, McNeil YR, Cheng AC, **Celermajer**

- DS**, Stephens DP, Anstey NM. Sepsis-associated microvascular dysfunction measured by peripheral arterial tonometry: an observational study. *Crit Care*. 2009;13(5):R155.
246. Ilsaar R, Chawantanpipat C, Chan KH, Waugh R, Hennessy A, **Celermajer DS**, Ng MK. Measurement of pulmonary flow reserve in higher primates. *Clin Exp Pharmacol Physiol*. 2009;36(8):797-802.
247. Maple-Brown L, Hodge A, Cunningham J, **Celermajer DS**, O'Dea K. Risk factors for cardiovascular disease do not fully explain differences in carotid intima-media thickness between Indigenous and European Australians without diabetes. *Clin Endocrinol (Oxf)*. 2009;71(2):189-94.
248. Maple-Brown LJ, Cunningham J, Barry RE, Leylsey L, O'Rourke MF, **Celermajer DS**, O'Dea K. Impact of dyslipidaemia on arterial structure and function in urban indigenous Australians. *Atherosclerosis*. 2009;202(1):248-54.
249. Marijon E, **Celermajer DS**, Jouven X. Management of patients with subclinical rheumatic heart disease. *Int J Cardiol*. 2009;134(3):295-6.
250. Marijon E, **Celermajer DS**, Tafflet M, El-Haou S, Jani DN, Ferreira B, Mocumbi AO, Paquet C, Sidi D, Jouven X. Rheumatic heart disease screening by echocardiography: the inadequacy of World Health Organization criteria for optimizing the diagnosis of subclinical disease. *Circulation*. 2009;120(8):663-8.
251. Ou P, Marini D, **Celermajer DS**, Agnoletti G, Vouhe P, Sidi D, Bonnet D, Brunelle F. Non-invasive assessment of congenital pulmonary vein stenosis in children using cardiac-non-gated CT with 64-slice technology. *Eur J Radiol*. 2009;70(3):595-9.
252. Patel S, Drew BG, Nakhla S, Duffy SJ, Murphy AJ, Barter PJ, Rye KA, Chin-Dusting J, Hoang A, Sviridov D, **Celermajer DS**, Kingwell BA. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. *J Am Coll Cardiol*. 2009;53(11):962-71.
253. Patel S, Puranik R, Nakhla S, Lundman P, Stocker R, Wang XS, Lambert G, Rye KA, Barter PJ, Nicholls SJ, **Celermajer DS**. Acute hypertriglyceridaemia in humans increases the triglyceride content and decreases the anti-inflammatory capacity of high density lipoproteins. *Atherosclerosis*. 2009;204(2):424-8.
254. Yeo TW, Lampah DA, Tjitra E, Gitawati R, Kenangalem E, Piera K, Granger DL, Lopansri BK, Weinberg JB, Price RN, Duffull SB, **Celermajer DS**, Anstey NM. Relationship of cell-free hemoglobin to impaired endothelial nitric oxide bioavailability and perfusion in severe falciparum malaria. *J Infect Dis*. 2009;200(10):1522-9.
255. Ayer JG, Harmer JA, Marks GB, Avolio A, **Celermajer DS**. Central arterial pulse wave augmentation is greater in girls than boys, independent of height. *J Hypertens*. 2010;28(2):306-13.
256. Ayer JG, Harmer JA, Steinbeck K, **Celermajer DS**. Postprandial vascular reactivity in obese and normal weight young adults. *Obesity (Silver Spring)*. 2010;18(5):945-51.
257. Ayer JG, Sholler GF, **Celermajer DS**. Left atrial size increases with body mass index in children. *Int J Cardiol*. 2010;141(1):61-7.
258. Ayer JG, Song C, Steinbeck K, **Celermajer DS**, Ben Freedman S. Increased tissue factor activity in monocytes from obese young adults. *Clin Exp Pharmacol Physiol*.

- 2010;37(11):1049-54.
259. Ban CR, Twigg SM, Franjic B, Brooks BA, **Celermajer D**, Yue DK, McLennan SV. Serum MMP-7 is increased in diabetic renal disease and diabetic diastolic dysfunction. *Diabetes Res Clin Pract.* 2010;87(3):335-41.
 260. Cordina R, **Celermajer D**. Late-onset pulmonary arterial hypertension after a successful atrial or arterial switch procedure for transposition of the great arteries. *Pediatr Cardiol.* 2010;31(2):238-41.
 261. Cordina RL, **Celermajer DS**. Chronic cyanosis and vascular function: implications for patients with cyanotic congenital heart disease. *Cardiol Young.* 2010;20(3):242-53.
 262. Cordina RL, **Celermajer DS**. Therapeutic approaches in adults with congenital heart disease-associated pulmonary arterial hypertension. *Eur Respir Rev.* 2010;19(118):300-7.
 263. Davis JS, Yeo TW, Piera KA, Woodberry T, **Celermajer DS**, Stephens DP, Anstey NM. Angiotensin-2 is increased in sepsis and inversely associated with nitric oxide-dependent microvascular reactivity. *Crit Care.* 2010;14(3):R89.
 264. Hamdan R, Mirochnik N, **Celermajer D**, Nassar P, Iserin L. Cor Triatriatum Sinister diagnosed in adult life with three dimensional transesophageal echocardiography. *BMC Cardiovasc Disord.* 2010;10:54.
 265. Ilsar R, Bailey BP, Dobbins TA, **Celermajer DS**. The relationship between pulmonary artery and pulmonary capillary wedge pressure for the diagnosis of pulmonary vascular disease. *Heart Lung Circ.* 2010;19(1):38-42.
 266. Ilsar R, Chawantanpipat C, Chan KH, Dobbins TA, Waugh R, Hennessy A, **Celermajer DS**, Ng MK. Doppler-derived pulmonary flow reserve detects pulmonary microvascular obstruction in high primates. *Heart Lung Circ.* 2010;19(10):592-4.
 267. Ilsar R, Chawantanpipat C, Chan KH, Dobbins TA, Waugh R, Hennessy A, **Celermajer DS**, Ng MK. Measurement of pulmonary flow reserve and pulmonary index of microcirculatory resistance for detection of pulmonary microvascular obstruction. *PLoS One.* 2010;5(3):e9601.
 268. Ilsar R, Levitt J, Ng MK, Kritharides L, Adams MR, **Celermajer DS**. Bosentan and improved pulmonary endothelial function in pulmonary arterial hypertension. *Eur Respir J.* 2010;36(6):1483-5.
 269. Lau EM, Yee BJ, Grunstein RR, **Celermajer DS**. Patent foramen ovale and obstructive sleep apnea: a new association? *Sleep Med Rev.* 2010;14(6):391-5.
 270. Mackie FE, Rosenberg AR, Harmer JA, Kainer G, **Celermajer DS**. HMG CoA reductase inhibition and endothelial function in children with chronic kidney disease (CKD)—a pilot study. *Acta Paediatr.* 2010;99(3):457-9.
 271. Patel S, Chung SH, White G, Bao S, **Celermajer DS**. The "atheroprotective" mediators apolipoprotein A-I and Foxp3 are over-abundant in unstable carotid plaques. *Int J Cardiol.* 2010;145(2):183-7.
 272. Patel S, Di Bartolo BA, Nakhla S, Heather AK, Mitchell TW, Jessup W, **Celermajer DS**, Barter PJ, Rye KA. Anti-inflammatory effects of apolipoprotein A-I in the rabbit. *Atherosclerosis.* 2010;212(2):392-7.

273. Puranik R, Muthurangu V, **Celermajer DS**, Taylor AM. Congenital heart disease and multi-modality imaging. *Heart Lung Circ*. 2010;19(3):133-44.
274. Roberts P, Spina R, Vallely M, Wilson M, Bailey B, **Celermajer DS**. Percutaneous tricuspid valve replacement for a stenosed bioprosthesis. *Circ Cardiovasc Interv*. 2010;3(4):e14-5.
275. Sieveking DP, Lim P, Chow RW, Dunn LL, Bao S, McGrath KC, Heather AK, Handelsman DJ, **Celermajer DS**, Ng MK. A sex-specific role for androgens in angiogenesis. *J Exp Med*. 2010;207(2):345-52.
276. Silversides CK, Dore A, Poirier N, Taylor D, Harris L, Greutmann M, Benson L, Baumgartner H, **Celermajer D**, Therrien J. Canadian Cardiovascular Society 2009 Consensus Conference on the management of adults with congenital heart disease: shunt lesions. *Can J Cardiol*. 2010;26(3):e70-9.
277. Silversides CK, Marelli A, Beauchesne L, Dore A, Kiess M, Salehian O, Bradley T, Colman J, Connelly M, Harris L, Khairy P, Mital S, Niwa K, Oechslin E, Poirier N, Schwerzmann M, Taylor D, Vonder Muhll I, Baumgartner H, Benson L, **Celermajer D**, Greutmann M, Horlick E, Landzberg M, Meijboom F, Mulder B, Warnes C, Webb G, Therrien J. Canadian Cardiovascular Society 2009 Consensus Conference on the management of adults with congenital heart disease: executive summary. *Can J Cardiol*. 2010;26(3):143-50.
278. Wang Y, Liu H, McKenzie G, Witting PK, Stasch JP, Hahn M, Changsirivathanathamrong D, Wu BJ, Ball HJ, Thomas SR, Kapoor V, **Celermajer DS**, Mellor AL, Keaney JF, Jr., Hunt NH, Stocker R. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. *Nat Med*. 2010;16(3):279-85.
279. Yeo TW, Lampah DA, Tjitra E, Gitawati R, Darcy CJ, Jones C, Kenangalem E, McNeil YR, Granger DL, Lopansri BK, Weinberg JB, Price RN, Duffull SB, **Celermajer DS**, Anstey NM. Increased asymmetric dimethylarginine in severe falciparum malaria: association with impaired nitric oxide bioavailability and fatal outcome. *PLoS Pathog*. 2010;6(4):e1000868.
280. Ayer JG, Belousova E, Harmer JA, David C, Marks GB, **Celermajer DS**. Maternal cigarette smoking is associated with reduced high-density lipoprotein cholesterol in healthy 8-year-old children. *Eur Heart J*. 2011;32(19):2446-53.
281. Ayer JG, Belousova EG, Harmer JA, Toelle B, **Celermajer DS**, Marks GB. Lung function is associated with arterial stiffness in children. *PLoS One*. 2011;6(10):e26303.
282. Ayer JG, Harmer JA, David C, K SS, Seale JP, **Celermajer DS**. Severe obesity is associated with impaired arterial smooth muscle function in young adults. *Obesity (Silver Spring)*. 2011;19(1):54-60.
283. **Celermajer DS**. Do Childhood Risk Factors Affect Arterial Structure and Function? 2011.
284. Changsirivathanathamrong D, Wang Y, Rajbhandari D, Maghzal GJ, Mak WM, Woolfe C, Duflou J, GebSKI V, dos Remedios CG, **Celermajer DS**, Stocker R. Tryptophan metabolism to kynurenine is a potential novel contributor to hypotension in human sepsis. *Crit Care Med*. 2011;39(12):2678-83.
285. Davis JS, Darcy CJ, Yeo TW, Jones C, McNeil YR, Stephens DP, **Celermajer DS**, Anstey NM. Asymmetric dimethylarginine, endothelial nitric oxide bioavailability and mortality in sepsis. *PLoS One*. 2011;6(2):e17260.
286. Iyer NR, Lau EM, IIsar R, **Celermajer DS**. Treatment responsiveness in pulmonary arterial

- hypertension—preliminary report on serial intra-arterial Doppler flow velocity waveform measurements. *Int J Cardiol.* 2011;153(2):219-21.
287. Jouven X, Escolano S, **Celermajer D**, Empana JP, Bingham A, Hermine O, Desnos M, Perier MC, Marijon E, Ducimetiere P. Heart rate and risk of cancer death in healthy men. *PLoS One.* 2011;6(8):e21310.
288. Lau EM, Manes A, **Celermajer DS**, Galie N. Early detection of pulmonary vascular disease in pulmonary arterial hypertension: time to move forward. *Eur Heart J.* 2011;32(20):2489-98.
289. Levy M, **Celermajer DS**, Bourges-Petit E, Del Cerro MJ, Bajolle F, Bonnet D. Add-on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension. *J Pediatr.* 2011;158(4):584-8.
290. Marijon E, Tafflet M, **Celermajer DS**, Dumas F, Perier MC, Mustafic H, Toussaint JF, Desnos M, Rieu M, Benameur N, Le Heuzey JY, Empana JP, Jouven X. Sports-related sudden death in the general population. *Circulation.* 2011;124(6):672-81.
291. Marshall NS, Ayer JG, Toelle BG, Harmer JA, Phillips CL, Grunstein RR, **Celermajer DS**, Marks GB. Snoring is not associated with adverse effects on blood pressure, arterial structure or function in 8-year-old children: the Childhood Asthma Prevention Study (CAPS). *J Paediatr Child Health.* 2011;47(8):518-23.
292. Morgan PE, Pattison DI, Talib J, Summers FA, Harmer JA, **Celermajer DS**, Hawkins CL, Davies MJ. High plasma thiocyanate levels in smokers are a key determinant of thiol oxidation induced by myeloperoxidase. *Free Radic Biol Med.* 2011;51(9):1815-22.
293. Ng AC, Chung T, Yong AS, Wong HS, Chow V, **Celermajer DS**, Kritharides L. Long-term cardiovascular and noncardiovascular mortality of 1023 patients with confirmed acute pulmonary embolism. *Circ Cardiovasc Qual Outcomes.* 2011;4(1):122-8.
294. Plichart M, **Celermajer DS**, Zureik M, Helmer C, Jouven X, Ritchie K, Tzourio C, Ducimetiere P, Empana JP. Carotid intima-media thickness in plaque-free site, carotid plaques and coronary heart disease risk prediction in older adults. The Three-City Study. *Atherosclerosis.* 2011;219(2):917-24.
295. Roberts PA, Boudjemline Y, Cheatham JP, Eicken A, Ewert P, McElhinney DB, Hill SL, Berger F, Khan D, Schranz D, Hess J, Ezekowitz MD, **Celermajer D**, Zahn E. Percutaneous tricuspid valve replacement in congenital and acquired heart disease. *J Am Coll Cardiol.* 2011;58(2):117-22.
296. Skilton MR, Maple-Brown LJ, Kapellas K, **Celermajer DS**, Bartold M, Brown A, O'Dea K, Slade GD, Jamieson LM. The effect of a periodontal intervention on cardiovascular risk markers in Indigenous Australians with periodontal disease: the PerioCardio study. *BMC Public Health.* 2011;11:729.
297. Skilton MR, Viikari JS, Juonala M, Laitinen T, Lehtimäki T, Taittonen L, Kahonen M, **Celermajer DS**, Raitakari OT. Fetal growth and preterm birth influence cardiovascular risk factors and arterial health in young adults: the Cardiovascular Risk in Young Finns Study. *Arterioscler Thromb Vasc Biol.* 2011;31(12):2975-81.
298. Smadja DM, Mauge L, Gaussem P, d'Audigier C, Israel-Biet D, **Celermajer DS**, Bonnet D, Levy M. Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension. *Angiogenesis.* 2011;14(1):17-27.

299. **Celermajer DS**. Manipulating nature: Might there be a cardiovascular price to pay for the miracle of assisted conception? *Circulation*. 2012;125(15):1832-4.
300. **Celermajer DS**, Chow CK, Marijon E, Anstey NM, Woo KS. Cardiovascular disease in the developing world: prevalences, patterns, and the potential of early disease detection. *J Am Coll Cardiol*. 2012;60(14):1207-16.
301. Cordina RL, **Celermajer DS**, McGuire MA. Systemic venous anatomy in congenital heart disease: implications for electrophysiologic testing and catheter ablation. *J Interv Card Electrophysiol*. 2012;33(2):143-9.
302. Dalton B, McNeil K, Keogh A, Williams T, Proudman S, Gabbay E, Kotlyar E, Weintraub R, Kermeen F, **Celermajer D**, Boland J. Design and delivery of an e-learning curriculum for physicians involved in the management of pulmonary hypertension. *Int J Clin Pract*. 2012;66(11):1117-24.
303. Don GW, Joseph F, **Celermajer DS**, Corte TJ. Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan. *Intern Med J*. 2012;42(12):1351-4.
304. Flammer AJ, Anderson T, **Celermajer DS**, Creager MA, Deanfield J, Ganz P, Hamburg NM, Luscher TF, Shechter M, Taddei S, Vita JA, Lerman A. The assessment of endothelial function: from research into clinical practice. *Circulation*. 2012;126(6):753-67.
305. Kwok T, Chook P, Qiao M, Tam L, Poon YK, Ahuja AT, Woo J, **Celermajer DS**, Woo KS. Vitamin B-12 supplementation improves arterial function in vegetarians with subnormal vitamin B-12 status. *J Nutr Health Aging*. 2012;16(6):569-73.
306. Lau EM, Iyer N, IIsar R, Bailey BP, Adams MR, **Celermajer DS**. Abnormal pulmonary artery stiffness in pulmonary arterial hypertension: in vivo study with intravascular ultrasound. *PLoS One*. 2012;7(3):e33331.
307. Marijon E, Mirabel M, **Celermajer DS**, Jouven X. Rheumatic heart disease. *Lancet*. 2012;379(9819):953-64.
308. Mirabel M, **Celermajer DS**, Ferreira B, Tafflet M, Perier MC, Karam N, Mocumbi AO, Jani DN, Sidi D, Jouven X, Marijon E. Screening for rheumatic heart disease: evaluation of a simplified echocardiography-based approach. *Eur Heart J Cardiovasc Imaging*. 2012;13(12):1024-9.
309. Mojtaba Golzan S, Leaney J, Cordina R, Avolio A, **Celermajer DS**, Graham SL. Spontaneous retinal venous pulsatility in patients with cyanotic congenital heart disease. *Heart Vessels*. 2012;27(6):618-23.
310. Morton J, Zoungas S, Li Q, Patel AA, Chalmers J, Woodward M, **Celermajer DS**, Beulens JW, Stolk RP, Glasziou P, Ng MK, Group AC. Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy: results of the ADVANCE study. *Diabetes Care*. 2012;35(11):2201-6.
311. O'Meagher S, Munoz PA, Alison JA, Young IH, Tanous DJ, **Celermajer DS**, Puranik R. Exercise capacity and stroke volume are preserved late after tetralogy repair, despite severe right ventricular dilatation. *Heart*. 2012;98(21):1595-9.
312. Rangan AM, Flood VL, Denyer G, Ayer JG, Webb KL, Marks GB, **Celermajer DS**, Gill TP. The effect of dairy consumption on blood pressure in mid-childhood: CAPS cohort study. *Eur J Clin Nutr*. 2012;66(6):652-7.

313. Rose ML, Strange G, King I, Arnup S, Vidmar S, O'Donnell C, Kermeen F, Grigg L, Weintraub RG, **Celermajer DS**. Congenital heart disease-associated pulmonary arterial hypertension: preliminary results from a novel registry. *Intern Med J*. 2012;42(8):874-9.
314. Skilton MR, Ayer JG, Harmer JA, Webb K, Leeder SR, Marks GB, **Celermajer DS**. Impaired fetal growth and arterial wall thickening: a randomized trial of omega-3 supplementation. *Pediatrics*. 2012;129(3):e698-703.
315. Skilton MR, Sullivan TR, Ayer JG, Harmer JA, Toelle BG, Webb K, Marks GB, **Celermajer DS**. Carotid extra-medial thickness in childhood: early life effects on the arterial adventitia. *Atherosclerosis*. 2012;222(2):478-82.
316. Talib J, Pattison DI, Harmer JA, **Celermajer DS**, Davies MJ. High plasma thiocyanate levels modulate protein damage induced by myeloperoxidase and perturb measurement of 3-chlorotyrosine. *Free Radic Biol Med*. 2012;53(1):20-9.
317. Thakkar V, Stevens WM, Prior D, Moore OA, Byron J, Liew D, Patterson K, Hissaria P, Roddy J, Zochling J, Sahhar J, Nash P, Tymms K, **Celermajer D**, Gabbay E, Youssef P, Proudman SM, Nikpour M. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study. *Arthritis Res Ther*. 2012;14(3):R143.
318. Ting RD, Keech AC, Drury PL, Donoghoe MW, Hedley J, Jenkins AJ, Davis TM, Lehto S, **Celermajer D**, Simes RJ, Rajamani K, Stanton K, Investigators FS. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. *Diabetes Care*. 2012;35(2):218-25.
319. Zahnd G, Vray D, Serusclat A, Alibay D, Bartold M, Brown A, Durand M, Jamieson LM, Kapellas K, Maple-Brown LJ, O'Dea K, Moulin P, **Celermajer DS**, Skilton MR. Longitudinal displacement of the carotid wall and cardiovascular risk factors: associations with aging, adiposity, blood pressure and periodontal disease independent of cross-sectional distensibility and intima-media thickness. *Ultrasound Med Biol*. 2012;38(10):1705-15.
320. Beurtheret S, Mordant P, Paoletti X, Marijon E, **Celermajer DS**, Leger P, Pavie A, Combes A, Leprince P. Emergency circulatory support in refractory cardiogenic shock patients in remote institutions: a pilot study (the cardiac-RESCUE program). *Eur Heart J*. 2013;34(2):112-20.
321. Blyton DM, Skilton MR, Edwards N, Hennessy A, **Celermajer DS**, Sullivan CE. Treatment of sleep disordered breathing reverses low fetal activity levels in preeclampsia. *Sleep*. 2013;36(1):15-21.
322. Canniffe C, Ou P, Walsh K, Bonnet D, **Celermajer D**. Hypertension after repair of aortic coarctation—a systematic review. *Int J Cardiol*. 2013;167(6):2456-61.
323. **Celermajer DS**, Neal B. Excessive sodium intake and cardiovascular disease: a-salting our vessels. *J Am Coll Cardiol*. 2013;61(3):344-5.
324. Cordina R, O'Meagher S, Gould H, Rae C, Kemp G, Pasco JA, **Celermajer DS**, Singh N. Skeletal muscle abnormalities and exercise capacity in adults with a Fontan circulation. *Heart*. 2013;99(20):1530-4.
325. Cordina RL, O'Meagher S, Karmali A, Rae CL, Liess C, Kemp GJ, Puranik R, Singh N, **Celermajer DS**. Resistance training improves cardiac output, exercise capacity and tolerance to positive airway pressure in Fontan physiology. *Int J Cardiol*. 2013;168(2):780-

8.

326. Hu YJ, Wei AN, Chook P, Yin Y, Cheng W, Wu MJ, **Celermajer DS**, Woo KS. Impact of non-cardiovascular surgery on reactive hyperaemia and arterial endothelial function. *Clin Exp Pharmacol Physiol*. 2013;40(7):466-72.
327. Kapellas K, Do LG, Bartold PM, Skilton MR, Maple-Brown LJ, O'Dea K, Brown A, **Celermajer DS**, Slade GD, Jamieson LM. Effects of full-mouth scaling on the periodontal health of Indigenous Australians: a randomized controlled trial. *J Clin Periodontol*. 2013;40(11):1016-24.
328. Ladouceur M, Kachenoura N, Lefort M, Redheuil A, Bonnet D, **Celermajer DS**, Iserin L, Mousseaux E. Structure and function of the ascending aorta in palliated transposition of the great arteries. *Int J Cardiol*. 2013;165(3):458-62.
329. Lau EM, Jaijee SK, Melehan KL, Wong KK, Yee BJ, Grunstein RR, **Celermajer DS**. Prevalence of patent foramen ovale and its impact on oxygen desaturation in obstructive sleep apnea. *Int J Cardiol*. 2013;165(1):35-40.
330. Lau EM, Morgan PE, Belousova EG, Toelle BG, Ayer JG, **Celermajer DS**, Marks GB. Asymmetric dimethylarginine and asthma: results from the Childhood Asthma Prevention Study. *Eur Respir J*. 2013;41(5):1234-7.
331. Levy M, Bonnet D, Mauge L, **Celermajer DS**, Gaussem P, Smadja DM. Circulating endothelial cells in refractory pulmonary hypertension in children: markers of treatment efficacy and clinical worsening. *PLoS One*. 2013;8(6):e65114.
332. Levy M, **Celermajer D**, Szezepanski I, Boudjemline Y, Bonnet D. Do tertiary paediatric hospitals deal with the same spectrum of paediatric pulmonary hypertension as multicentre registries? *Eur Respir J*. 2013;41(1):236-9.
333. Low AJ, Fowler D, Manghani MK, Young I, Garsia R, Torzillo P, Youssef P, **Celermajer DS**. Screening and treating pulmonary arterial hypertension in a tertiary hospital-based multidisciplinary clinic: the first 200 patients. *Intern Med J*. 2013;43(1):32-7.
334. Marijon E, Bougouin W, **Celermajer DS**, Perier MC, Benameur N, Lamhaut L, Karam N, Dumas F, Tafflet M, Prugger C, Mustafic H, Rifler JP, Desnos M, Le Heuzey JY, Spaulding CM, Avillach P, Cariou A, Empana JP, Jouven X. Major regional disparities in outcomes after sudden cardiac arrest during sports. *Eur Heart J*. 2013;34(47):3632-40.
335. Marijon E, Bougouin W, **Celermajer DS**, Perier MC, Dumas F, Benameur N, Karam N, Lamhaut L, Tafflet M, Mustafic H, de Deus NM, Le Heuzey JY, Desnos M, Avillach P, Spaulding C, Cariou A, Prugger C, Empana JP, Jouven X. Characteristics and outcomes of sudden cardiac arrest during sports in women. *Circ Arrhythm Electrophysiol*. 2013;6(6):1185-91.
336. Marijon E, Bougouin W, Perier MC, **Celermajer DS**, Jouven X. Incidence of sports-related sudden death in France by specific sports and sex. *JAMA*. 2013;310(6):642-3.
337. Marijon E, Tafflet M, Antero-Jacquemin J, El Helou N, Berthelot G, **Celermajer DS**, Bougouin W, Combes N, Hermine O, Empana JP, Rey G, Toussaint JF, Jouven X. Mortality of French participants in the Tour de France (1947-2012). *Eur Heart J*. 2013;34(40):3145-50.
338. Offen S, **Celermajer D**, Semsarian C, Puranik R. The role of diastolic filling in preserving left ventricular stroke volume--an MRI study. *Int J Cardiol*. 2013;168(2):1596-8.

339. O'Meagher S, Choudhary P, Duflou J, Puranik R, **Celermajer DS**. Causes of death in tetralogy of Fallot in adults--an autopsy study. *Int J Cardiol*. 2013;168(2):1547-8.
340. Ou P, Khraiche D, **Celermajer DS**, Agnoletti G, Le Quan Sang KH, Thalabard JC, Quintin M, Raisy O, Vouhe P, Sidi D, Bonnet D. Mechanisms of coronary complications after the arterial switch for transposition of the great arteries. *J Thorac Cardiovasc Surg*. 2013;145(5):1263-9.
341. Plichart M, Thomas F, Empana JP, Bean K, Perier MC, **Celermajer DS**, Hanon O, Danchin N, Pannier B, Jouven X. Gender-specific trends in heart rate in the general population from 1992-2007: a study of 226,288 French adults. *Eur J Prev Cardiol*. 2013;20(1):61-72.
342. Schuurin MJ, Bouma BJ, Cordina R, Gatzoulis MA, Budts W, Mullen MP, Vis JC, **Celermajer D**, Mulder BJ. Treatment of segmental pulmonary artery hypertension in adults with congenital heart disease. *Int J Cardiol*. 2013;164(1):106-10.
343. Simonneau G, Gatzoulis MA, Adatia I, **Celermajer D**, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R. Updated clinical classification of pulmonary hypertension. *J Am Coll Cardiol*. 2013;62(25 Suppl):D34-41.
344. Simpson PJ, Hoyos CM, **Celermajer D**, Liu PY, Ng MK. Effects of continuous positive airway pressure on endothelial function and circulating progenitor cells in obstructive sleep apnoea: a randomised sham-controlled study. *Int J Cardiol*. 2013;168(3):2042-8.
345. Skilton MR, Marks GB, Ayer JG, Garden FL, Garnett SP, Harmer JA, Leeder SR, Toelle BG, Webb K, Baur LA, **Celermajer DS**. Weight gain in infancy and vascular risk factors in later childhood. *Pediatrics*. 2013;131(6):e1821-8.
346. Skilton MR, Mikkila V, Wurtz P, Ala-Korpela M, Sim KA, Soininen P, Kangas AJ, Viikari JS, Juonala M, Laitinen T, Lehtimäki T, Taittonen L, Kahonen M, **Celermajer DS**, Raitakari OT. Fetal growth, omega-3 (n-3) fatty acids, and progression of subclinical atherosclerosis: preventing fetal origins of disease? The Cardiovascular Risk in Young Finns Study. *Am J Clin Nutr*. 2013;97(1):58-65.
347. Skilton MR, Raitakari OT, **Celermajer DS**. High intake of dietary long-chain omega-3 fatty acids is associated with lower blood pressure in children born with low birth weight: NHANES 2003-2008. *Hypertension*. 2013;61(5):972-6.
348. Amarasena N, Kapellas K, Skilton, Maple-Brown L, Brown A, O'Dea K, **Celermajer D**, Jamieson L. Associations with dental caries experience among a convenience sample of Aboriginal Australian adults. *Aust Dent J*. 2014.
349. Amarasena N, Kapellas K, Skilton M, Maple-Brown L, Brown A, Bartold PM, O'Dea K, **Celermajer D**, Slade G, Jamieson LM. Oral health behaviours and perceptions reported by Indigenous Australians living in Darwin, Northern Territory. *Community Dent Health*. 2014;31(1):57-61.
350. Bougouin W, Marijon E, Puymirat E, Defaye P, **Celermajer DS**, Le Heuzey JY, Boveda S, Kacet S, Mabo P, Barnay C, Da Costa A, Deharo JC, Daubert JC, Ferrieres J, Simon T, Danchin N, Investigators F-MR. Incidence of sudden cardiac death after ventricular fibrillation complicating acute myocardial infarction: a 5-year cause-of-death analysis of the FAST-MI 2005 registry. *Eur Heart J*. 2014;35(2):116-22.
351. Bouzeman A, Marijon E, de Guillebon M, Ladouceur M, Duthoit G, Amet D, Martins R,

- Otmani A, Lavergne T, Bordachar P, **Celermajer DS**, Thambo JB, Iserin L, Combes N. Implantable cardiac defibrillator among adults with transposition of the great arteries and atrial switch operation: case series and review of literature. *Int J Cardiol.* 2014;177(1):301-6.
352. Chan KH, Simpson PJ, Yong AS, Dunn LL, Chawantanpipat C, Hsu C, Yu Y, Keech AC, **Celermajer DS**, Ng MK. The relationship between endothelial progenitor cell populations and epicardial and microvascular coronary disease—a cellular, angiographic and physiologic study. *PLoS One.* 2014;9(4):e93980.
353. Chow V, Ng AC, Seccombe L, Chung T, Thomas L, **Celermajer DS**, Peters M, Kritharides L. Impaired 6-min walk test, heart rate recovery and cardiac function post pulmonary embolism in long-term survivors. *Respir Med.* 2014;108(10):1556-65.
354. Chow V, Yeoh T, Ng AC, Pasqualon T, Scott E, Plater J, Whitwell B, Hanzek D, Chung T, Thomas L, **Celermajer DS**, Kritharides L. Asymptomatic left ventricular dysfunction with long-term clozapine treatment for schizophrenia: a multicentre cross-sectional cohort study. *Open Heart.* 2014;1(1):e000030.
355. Cordina R, Grieve S, Barnett M, Lagopoulos J, Malitz N, **Celermajer DS**. Brain volumetric, regional cortical thickness and radiographic findings in adults with cyanotic congenital heart disease. *Neuroimage Clin.* 2014;4:319-25.
356. Dennis M, Laarkson M, Padang R, Tanous DJ, Robinson P, Pressley L, O'Meagher S, **Celermajer D**, Puranik R. Long term followup of aortic root size after repair of tetralogy of Fallot. *Int J Cardiol.* 2014;177(1):136-8.
357. d'Udekem Y, Iyengar AJ, Galati JC, Forsdick V, Weintraub RG, Wheaton GR, Bullock A, Justo RN, Grigg LE, Sholler GF, Hope S, Radford DJ, Gentles TL, **Celermajer DS**, Winlaw DS. Redefining expectations of long-term survival after the Fontan procedure: twenty-five years of follow-up from the entire population of Australia and New Zealand. *Circulation.* 2014;130(11 Suppl 1):S32-8.
358. Dunn LL, Simpson PJ, Prosser HC, Lecce L, Yuen GS, Buckle A, Sieveking DP, Vanags LZ, Lim PR, Chow RW, Lam YT, Clayton Z, Bao S, Davies MJ, Stadler N, **Celermajer DS**, Stocker R, Bursill CA, Cooke JP, Ng MK. A critical role for thioredoxin-interacting protein in diabetes-related impairment of angiogenesis. *Diabetes.* 2014;63(2):675-87.
359. Ganigara M, Collins N, Tanous D, **Celermajer D**, Puranik R. Anomalous left anterior descending coronary artery from the pulmonary artery—the role of cardiac MRI. *Int J Cardiol.* 2014;172(1):e172-4.
360. Ganigara M, Tanous D, **Celermajer D**, Puranik R. The role of cardiac MRI in the diagnosis and management of sinus venosus atrial septal defect. *Ann Pediatr Cardiol.* 2014;7(2):160-2.
361. Harmer JA, Keech AC, Veillard AS, Skilton MR, Marwick TH, Watts GF, Meredith IT, **Celermajer DS**, Investigators FVS. Cigarette smoking and albuminuria are associated with impaired arterial smooth muscle function in patients with type 2 diabetes mellitus: a FIELD substudy. *Diabetes Res Clin Pract.* 2014;106(2):328-36.
362. Iyengar AJ, Winlaw DS, Galati JC, **Celermajer DS**, Wheaton GR, Gentles TL, Grigg LE, Weintraub RG, Bullock A, Justo RN, d'Udekem Y. Trends in Fontan surgery and risk factors for early adverse outcomes after Fontan surgery: the Australia and New Zealand Fontan Registry experience. *J Thorac Cardiovasc Surg.* 2014;148(2):566-75.

363. Iyengar AJ, Winlaw DS, Galati JC, Gentles TL, Weintraub RG, Justo RN, Wheaton GR, Bullock A, **Celermajer DS**, d'Udekem Y. The Australia and New Zealand Fontan Registry: description and initial results from the first population-based Fontan registry. *Intern Med J*. 2014;44(2):148-55.
364. Iyengar AJ, Winlaw DS, Galati JC, Wheaton GR, Gentles TL, Grigg LE, Justo RN, Radford DJ, Weintraub RG, Bullock A, **Celermajer DS**, d'Udekem Y, Australia, New Zealand Fontan R. The extracardiac conduit Fontan procedure in Australia and New Zealand: hypoplastic left heart syndrome predicts worse early and late outcomes. *Eur J Cardiothorac Surg*. 2014;46(3):465-73; discussion 73.
365. Kapellas K, Jamieson LM, Do LG, Bartold PM, Wang H, Maple-Brown LJ, Sullivan D, O'Dea K, Brown A, **Celermajer DS**, Slade GD, Skilton MR. Associations between periodontal disease and cardiovascular surrogate measures among Indigenous Australians. *Int J Cardiol*. 2014;173(2):190-6.
366. Kapellas K, Maple-Brown LJ, Jamieson LM, Do LG, O'Dea K, Brown A, Cai TY, Anstey NM, Sullivan DR, Wang H, **Celermajer DS**, Slade GD, Skilton MR. Effect of periodontal therapy on arterial structure and function among aboriginal australians: a randomized, controlled trial. *Hypertension*. 2014;64(4):702-8.
367. Kapellas K, Skilton MR, Maple-Brown LJ, Do LG, Bartold PM, O'Dea K, Brown A, **Celermajer DS**, Jamieson LM. Periodontal disease and dental caries among Indigenous Australians living in the Northern Territory, Australia. *Aust Dent J*. 2014;59(1):93-9.
368. Lau EM, Abelson D, Dwyer N, Yu Y, Ng MK, **Celermajer DS**. Assessment of ventriculo-arterial interaction in pulmonary arterial hypertension using wave intensity analysis. *Eur Respir J*. 2014;43(6):1804-7.
369. Lau EM, Bailey DL, Bailey EA, Torzillo PJ, Roach PJ, Schembri GP, Corte TJ, **Celermajer DS**. Pulmonary hypertension leads to a loss of gravity dependent redistribution of regional lung perfusion: a SPECT/CT study. *Heart*. 2014;100(1):47-53.
370. Lau EM, **Celermajer DS**. Protecting our children from environmental tobacco smoke: one of our great healthcare challenges. *Eur Heart J*. 2014;35(36):2452-3.
371. Lau EM, Vanderpool RR, Choudhary P, Simmons LR, Corte TJ, Argiento P, D'Alto M, Naeije R, **Celermajer DS**. Dobutamine stress echocardiography for the assessment of pressure-flow relationships of the pulmonary circulation. *Chest*. 2014;146(4):959-66.
372. Martinez GJ, Bailey BP, **Celermajer DS**, Patel S. A safe and easy technique to sample the coronary sinus—facilitating a closer look at cardiac disease. *Int J Cardiol*. 2014;176(3):1321-2.
373. Martinez GJ, Ng BH, Wilson MK, Pasupati S, Robinson DA, Cartwright BL, Adams MR, **Celermajer DS**, Ng MK. Transcatheter valve-in-valve replacement in complex cyanotic congenital heart disease with a single ventricle. *JACC Cardiovasc Interv*. 2014;7(10):e133-5.
374. Martinez GJ, Seco M, Jaijee SK, Adams MR, Cartwright BL, Forrest P, **Celermajer DS**, Valley MP, Wilson MK, Ng MK. Introduction of an interdisciplinary heart team-based transcatheter aortic valve implantation programme: short and mid-term outcomes. *Intern Med J*. 2014;44(9):876-83.
375. McGrath KC, Li XH, Whitworth PT, Kasz R, Tan JT, McLennan SV, **Celermajer DS**, Barter

- PJ, Rye KA, Heather AK. High density lipoproteins improve insulin sensitivity in high-fat diet-fed mice by suppressing hepatic inflammation. *J Lipid Res.* 2014;55(3):421-30.
376. Nayyar D, Muthiah K, Kumarasinghe G, Hettiarachchi R, **Celermajer D**, Kotlyar E, Keogh A. Imatinib for the treatment of pulmonary arterial hypertension and pulmonary capillary hemangiomatosis. *Pulm Circ.* 2014;4(2):342-5.
377. O'Meagher S, Ganigara M, Munoz P, Tanous DJ, Chard RB, **Celermajer DS**, Puranik R. Right ventricular outflow tract enlargement prior to pulmonary valve replacement is associated with poorer structural and functional outcomes, in adults with repaired Tetralogy of Fallot. *Heart Lung Circ.* 2014;23(5):482-8.
378. O'Meagher S, Munoz PA, Muthurangu V, Robinson PJ, Malitz N, Tanous DJ, **Celermajer DS**, Puranik R. Mechanisms of maintained exercise capacity in adults with repaired tetralogy of Fallot. *Int J Cardiol.* 2014;177(1):178-81.
379. Padang R, Dennis M, Semsarian C, Bannon PG, Tanous DJ, **Celermajer DS**, Puranik R. Detection of serious complications by MR imaging in asymptomatic young adults with repaired coarctation of the aorta. *Heart Lung Circ.* 2014;23(4):332-8.
380. Skilton MR, Siitonen N, Wurtz P, Viikari JS, Juonala M, Seppala I, Laitinen T, Lehtimaki T, Taittonen L, Kahonen M, **Celermajer DS**, Raitakari OT. High birth weight is associated with obesity and increased carotid wall thickness in young adults: the cardiovascular risk in young Finns study. *Arterioscler Thromb Vasc Biol.* 2014;34(5):1064-8.
381. Skilton MR, Sullivan TR, Ayer JG, Garden FL, Harmer JA, Leeder SR, Toelle BG, Webb K, Marks GB, **Celermajer DS**. Weight gain in infancy is associated with carotid extra-medial thickness in later childhood. *Atherosclerosis.* 2014;233(2):370-4.
382. Szopos M, Poussineau N, Maday Y, Canniffe C, **Celermajer DS**, Bonnet D, Ou P. Computational modeling of blood flow in the aorta—insights into eccentric dilatation of the ascending aorta after surgery for coarctation. *J Thorac Cardiovasc Surg.* 2014;148(4):1572-82.
383. Woo KS, Kwok TC, **Celermajer DS**. Vegan diet, subnormal vitamin B-12 status and cardiovascular health. *Nutrients.* 2014;6(8):3259-73.
384. Amarasena N, Kapellas K, Brown A, Skilton MR, Maple-Brown LJ, Bartold MP, O'Dea K, **Celermajer D**, Slade GD, Jamieson L. Psychological distress and self-rated oral health among a convenience sample of Indigenous Australians. *J Public Health Dent.* 2015;75(2):126-33.
385. Arnott C, Skilton MR, Ruohonen S, Juonala M, Viikari JS, Kahonen M, Lehtimaki T, Laitinen T, **Celermajer DS**, Raitakari OT. Subtle increases in heart size persist into adulthood in growth restricted babies: the Cardiovascular Risk in Young Finns Study. *Open Heart.* 2015;2(1):e000265.
386. Ayer J, Charakida M, Deanfield JE, **Celermajer DS**. Lifetime risk: childhood obesity and cardiovascular risk. *Eur Heart J.* 2015;36(22):1371-6.
387. Bougouin W, Mustafic H, Marijon E, Murad MH, Dumas F, Barbouttis A, Jabre P, Beganton F, Empana JP, **Celermajer DS**, Cariou A, Jouven X. Gender and survival after sudden cardiac arrest: A systematic review and meta-analysis. *Resuscitation.* 2015;94:55-60.

388. Choudhary P, Canniffe C, Jackson DJ, Tanous D, Walsh K, **Celermajer DS**. Late outcomes in adults with coarctation of the aorta. *Heart*. 2015.
389. Choudhary P, Hsu CJ, Grieve S, Smillie C, Singarayar S, Semsarian C, Richmond D, Muthurangu V, **Celermajer DS**, Puranik R. Improving the diagnosis of LV non-compaction with cardiac magnetic resonance imaging. *Int J Cardiol*. 2015;181:430-6.
390. Cordina R, Leaney J, Golzan M, Grieve S, **Celermajer DS**, Graham SL. Ophthalmological consequences of cyanotic congenital heart disease: vascular parameters and nerve fibre layer. *Clin Experiment Ophthalmol*. 2015;43(2):115-23.
391. Cordina RL, Nakhla S, O'Meagher S, Leaney J, Graham S, **Celermajer DS**. Widespread endotheliopathy in adults with cyanotic congenital heart disease. *Cardiol Young*. 2015;25(3):511-9.
392. Fulcher J, Patel S, Nicholls SJ, Bao S, **Celermajer D**. Optical coherence tomography for serial in vivo imaging of aortic plaque in the rabbit: a preliminary experience. *Open Heart*. 2015;2(1):e000314.
393. Forsdick V, Iyengar AJ, Carins T, Gentles TL, Weintraub RG, **Celermajer DS**, d'Udekem Y. Unsatisfactory Early and Late Outcomes After Fontan Surgery Delayed to Adolescence and Adulthood. *Semin Thorac Cardiovasc Surg*. 2015;27(2):168-74.
394. Harmer JA, Keech AC, Veillard AS, Skilton MR, Marwick TH, Watts GF, Meredith IT, **Celermajer DS**. Fenofibrate effects on arterial endothelial function in adults with type 2 diabetes mellitus: A FIELD substudy. *Atherosclerosis*. 2015;242(1):295-302.
395. Lau EM, **Celermajer DS**, Naeije R. The emerging role of the contractile and vascular reserves in pulmonary arterial hypertension. *Eur Respir J*. 2015;45(6):1758-9.
396. Lau EM, Chemla D, Godinas L, Zhu K, Sitbon O, Savale L, Montani D, Jais X, **Celermajer DS**, Simonneau G, Humbert M, Herve P. Loss of Vascular Distensibility During Exercise is an Early Hemodynamic Marker of Pulmonary Vascular Disease. *Chest*. 2015.
397. Lau EM, Humbert M, **Celermajer DS**. Early detection of pulmonary arterial hypertension. *Nat Rev Cardiol*. 2015;12(3):143-55.
398. Luu Q, Choudhary P, Jackson D, Canniffe C, McGuire M, Chard R, **Celermajer DS**. Ebstein's Anomaly in Those Surviving to Adult Life - A Single Centre Experience. *Heart Lung Circ*. 2015.
399. Marijon E, Bougouin W, Karam N, Beganton F, Lamhaut L, Perier MC, Benameur N, Tafflet M, Beal G, Hagege A, Le Heuzey JY, Desnos M, Spaulding C, Carre F, Dumas F, **Celermajer DS**, Cariou A, Jouven X. Survival from sports-related sudden cardiac arrest: In sports facilities versus outside of sports facilities. *Am Heart J*. 2015;170(2):339-45.e1.
400. Marijon E, Bougouin W, Tafflet M, Karam N, Jost D, Lamhaut L, Beganton F, Pelloux P, Degrange H, Beal G, Tourtier JP, Hagege AA, Le Heuzey JY, Desnos M, Dumas F, Spaulding C, **Celermajer DS**, Cariou A, Jouven X. Population movement and sudden cardiac arrest location. *Circulation*. 2015;131(18):1546-54.
401. Martinez GJ, Robertson S, Barraclough J, Xia Q, Mallat Z, Bursill C, **Celermajer DS**, Patel S. Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients With an Acute Coronary Syndrome. *J Am Heart Assoc*. 2015;4(8):e002128.

402. Mirabel M, **Celermajer D**, Beraud AS, Jouven X, Marijon E, Hagege AA. Pocket-sized focused cardiac ultrasound: strengths and limitations. *Arch Cardiovasc Dis.* 2015;108(3):197-205.
403. O'Meagher S, Seneviratne M, Skilton MR, Munoz PA, Robinson PJ, Malitz N, Tanous DJ, **Celermajer DS**, Puranik R. Right Ventricular Mass is Associated with Exercise Capacity in Adults with Repaired Tetralogy of Fallot. *Pediatr Cardiol.* 2015.
404. Padang R, Ganigara M, O'Meagher S, Grieve SM, Bannon PG, **Celermajer DS**, Jeremy R, Semsarian C, Puranik R. Feasibility of using real-time CMR imaging to evaluate acute thoracic aortic response to exercise. *Int J Cardiol.* 2015;197:306-8.
405. Sharma T, Lau EM, Choudhary P, Torzillo PJ, Munoz PA, Simmons LR, Naeije R, **Celermajer DS**. Dobutamine stress for evaluation of right ventricular reserve in pulmonary arterial hypertension. *Eur Respir J.* 2015;45(3):700-8.
406. Skilton MR, Nakhla S, Ayer JG, Harmer JA, Toelle BG, Leeder SR, Jones G, Marks GB, **Celermajer DS**. Telomere length in early childhood: Early life risk factors and association with carotid intima-media thickness in later childhood. *Eur J Prev Cardiol.* 2015.
407. Skilton MR, Pakkala K, Viikari JS, Ronnema T, Simell O, Jula A, Niinikoski H, **Celermajer DS**, Raitakari OT. The association of dietary alpha-linolenic Acid with blood pressure and subclinical atherosclerosis in people born small for gestational age: the special turku coronary risk factor intervention project study. *J Pediatr.* 2015;166(5):1252-7 e2.
408. Strange G, Rose M, Kermeen F, O'Donnell C, Keogh A, Kotlyar E, Grigg L, Bullock A, Disney P, Dwyer N, Whitford H, Tanous D, Frampton C, Weintraub R, **Celermajer DS**. A Bi National Registry of Adults with Pulmonary Arterial Hypertension complicating Congenital Heart Disease. *Intern Med J.* 2015.
409. Yu Y, Wise SG, Michael PL, Bax DV, Yuen GS, Hiob MA, Yeo GC, Filipe EC, Dunn LL, Chan KH, Hajian H, **Celermajer DS**, Weiss AS, Ng MK. Characterization of Endothelial Progenitor Cell Interactions with Human Tropoelastin. *PLoS One.* 2015;10(6):e0131101.
410. Cai TY, Magnussen C, Haluska B, Johnson DW, Mottram PM, Isbel N, **Celermajer DS**, Marwick TH, Skilton MR. Carotid extra-medial thickness does not predict adverse cardiovascular outcomes in high-risk adults. *Diabetes Metab.* 2016.
411. Cai TY, Sullivan TR, Ayer JG, Harmer JA, Leeder SR, Toelle BG, Marks GB, **Celermajer DS**, Skilton MR. Carotid extramedial thickness is associated with local arterial stiffness in children. *J Hypertens.* 2016;34(1):109-15.
412. Chia EM, Lau EM, Xuan W, **Celermajer DS**, Thomas L. Exercise testing can unmask right ventricular dysfunction in systemic sclerosis patients with normal resting pulmonary artery pressure. *Int J Cardiol.* 2016;204:179-86.
413. Kizirian NV, Kong Y, Muirhead R, Brodie S, Garnett SP, Petocz P, Sim KA, **Celermajer DS**, Louie JC, Markovic TP, Ross GP, Ward LC, Brand-Miller JC, Skilton MR. Effects of a low-glycemic index diet during pregnancy on offspring growth, body composition, and vascular health: a pilot randomized controlled trial. *Am J Clin Nutr.* 2016;103(4):1073-82.
414. Krishnan A, Drak D, Bao S, **Celermajer DS**, Liu J. A model of early transient pressure overload simulating repair of aortic coarctation in childhood. *J Thorac Cardiovasc Surg.* 2016.

415. Kutty S, Rathod RH, Danford DFA, **Celermajer DS**. Role of imaging in the evaluation of single ventricle with the Fontan palliation. *Heart*. 2016;102(3):174-83.
416. Lau EM, Chemla D, Godinas L, Zhu K, Sitbon O, Savale L, Montani D, Jais X, **Celermajer DS**, Simonneau G, Humbert M, Herve P. Loss of Vascular Distensibility During Exercise Is an Early Hemodynamic Marker of Pulmonary Vascular Disease. *Chest*. 2016;149(2):353-61.
417. Lau EM, Godinas L, Sitbon O, Montani D, Savale L, Jais X, Lador F, Gunther S, **Celermajer DS**, Simonneau G, Humbert M, Chemla D, Herve P. Resting pulmonary artery pressure of 21-24 mmHg predicts abnormal exercise haemodynamics. *Eur Respir J*. 2016.
418. Offen S, Jackson D, Canniffe C, Choudhary P, **Celermajer DS**. Dextrocardia in Adults with Congenital Heart Disease. *Heart Lung Circ*. 2016;25(4):352-7.
419. Poh CL, Cochrane A, Galati JC, Bullock A, **Celermajer DS**, Gentles T, du Plessis K, Winlaw DS, Hornung T, Finucane K, d'Udekem Y. Ten-year outcomes of Fontan conversion in Australia and New Zealand demonstrate the superiority of a strategy of early conversiondagger. *Eur J Cardiothorac Surg*. 2016;49(2):530-5.
420. Seneviratne MG, Grieve SM, Figtree GA, Garsia R, **Celermajer DS**, Adelstein S, Puranik R. Prevalence, distribution and clinical correlates of myocardial fibrosis in systemic lupus erythematosus: a cardiac magnetic resonance study. *Lupus*. 2016;25(6):573-81.
421. Wilson TG, Iyengar AJ, Winlaw DS, Weintraub RG, Wheaton GR, Gentles TL, Ayer J, Grigg LE, Justo RN, Radford DJ, Bullock A, **Celermajer DS**, Dalziel K, Schilling C, d'Udekem Y. Use of ACE inhibitors in Fontan: Rational or irrational? *Int J Cardiol*. 2016;210:95-9.
422. Choudhary P, Nandakumar R, Greig H, Broadhurst P, Dean J, Puranik R, **Celermajer DS**, Hillis GS. Structural and electrical cardiac abnormalities are prevalent in asymptomatic adults with myotonic dystrophy. *Heart*. 2016:1-7.
423. Kapadia R, Choudhary P, Collins N, **Celermajer D**, Puranik R. Left Ventricular Non-compaction in Holt-Oram Syndrome. *Heart Lung Circ*. 2016;25(6):626-30.
424. Iyengar AJ, **Celermajer DS**, Winlaw DS, D'Udekem Y. Young and Free: Over 25 Years of Seminal Contributions to Complex Congenital Heart Disease From Australia & New Zealand. *Heart Lung Circ*. 2016;25(6):529-34.
425. Robertson S, Martinez GJ, Payet CA, Barraclough JY, **Celermajer DS**, Bursill C, Patel S. Colchicine Therapy in Acute Coronary Syndrome Patients acts on Caspase-1 to Suppress NLRP3 Inflammasome Monocyte Activation. *Clin Sci (Lond)*. 2016.
426. Tan JT, Prosser HC, Dunn LL, Vanags LZ, Ridiandries A, Tsatralis T, Leece L, Clayton ZE, Yuen SC, Robertson S, Lam YT, **Celermajer DS**, Ng MK, Bursill CA. High-Density Lipoproteins Rescue Diabetes-Impaired Angiogenesis via Scavenger Receptor Class B Type I. *Diabetes*. 2016;65(10):3091-103.
427. Skilton MR, Nakhla S, Ayer JG, Harmer JA, Toelle BG, Leeder SR, Jones G, Marks GB, **Celermajer DS**. Telomere length in early childhood: Early life risk factors and association with carotid intima-media thickness in later childhood. *Eur J Prev Cardiol*. 2016;23(10):1086-92.

428. Kapellas K, Mejia G, Bartold PM, Skilton MR, Maple-Brown LJ, Slade GD, O'Dea K, Brown A, **Celermajer DS**, Jamieson LM. Periodontal therapy and glycaemic control among individuals with type 2 diabetes: reflections from the PerioCardio study. *Int J Dent Hyg*. 2016.
429. Iyengar AJ, Winlaw DS, Galati JC, Wheaton GR, Gentles TL, Grigg LE, Justo RN, Radford DJ, Attard C, Weintraub RG, Bullock A, Sholler GS, **Celermajer DS**, d'Udekem Y. No difference between aspirin and warfarin after extracardiac Fontan in a propensity score analysis of 475 patients. *Eur J Cardiothorac Surg*. 2016.
430. Iyengar AJ, **Celermajer DS**, Winlaw DS, D'Udekem Y. Young and Free: Over 25 Years of Seminal Contributions to Complex Congenital Heart Disease From Australia & New Zealand. *Heart Lung Circ*. 2016;25(6):529-34.
431. Grimaldi A, Mocumbi AO, Freers J, Lachaud M, Mirabel M, Ferreira B, Narayanan K, **Celermajer DS**, Sidi D, Jouven X, Marijon E. Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. *Circulation*. 2016;133(24):2503-15.
432. Cordina R, von Klemperer K, Kempny A, West C, Senior R, **Celermajer DS**, Gatzoulis MA, Babu-Narayan SV, Li W. Echocardiographic Predictors of Mortality in Adults With a Fontan Circulation. *JACC Cardiovasc Imaging*. 2016.
433. Choudhary P, Nandakumar R, Greig H, Broadhurst P, Dean J, Puranik R, **Celermajer DS**, Hillis GS. Structural and electrical cardiac abnormalities are prevalent in asymptomatic adults with myotonic dystrophy. *Heart*. 2016;102(18):1472-8.
434. Callaghan FM, Arnott C, Figtree GA, Kutty S, **Celermajer DS**, Grieve SM. Quantifying right atrial filling and emptying: A 4D-flow MRI study. *J Magn Reson Imaging*. 2016.
435. Calderone A, Stevens W, Prior D, Nandurkar H, Gabbay E, Proudman SM, Williams T, **Celermajer D**, Sahhar J, Wong P, Thakkar V, Dwyer N, Wrobel J, Chin W, Liew D, Staples M, Buchbinder R, Nikpour M. M A multi-centre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol. *BMJ Open*. 2016
436. Amarasena N, Kapellas K, Skilton MR, Maple-Brown LJ, Brown A, Bartold M, O'Dea K, **Celermajer D**, Jamieson LM. Factors Associated with Routine Dental Attendance among Aboriginal Australians. *J Health Care Poor Underserved*. 2016;27(1a):67-80.
437. Bougouin W, Marijon E, Planquette B, Karam N, Dumas F, **Celermajer DS**, Jost D, Lamhaut L, Beganton F, Cariou A, Meyer G, Jouven X. Factors Associated With Pulmonary Embolism-Related Sudden Cardiac Arrest. *Circulation*. 2016;134(25):2125-7.
438. Carins TA, Shi WY, Iyengar AJ, Nisbet A, Forsdick V, Zannino D, Gentles T, Radford DJ, Justo R, **Celermajer DS**, Bullock A, Winlaw D, Wheaton G, Grigg L, d'Udekem Y. Long-term outcomes after first-onset arrhythmia in Fontan physiology. *J Thorac Cardiovasc Surg*. 2016; 152(5):1355-63.e1.
439. Clift P, **Celermajer D**. Managing adult Fontan patients: where do we stand? *Eur Respir Rev*. 2016; 25(142):438-50.

440. Raghuveer G, White DA, Hayman LL, Woo JG, Villafane J, **Celermajer D**, Ward KD, de Ferranti SD, Zachariah J. Cardiovascular Consequences of Childhood Secondhand Tobacco Smoke Exposure: Prevailing Evidence, Burden, and Racial and Socioeconomic Disparities: A Scientific Statement From the American Heart Association. *Circulation*. 2016; 134(16):e336-e59.
441. Gnanappa GK, **Celermajer DS**, Sholler GF, Gentles T, Winlaw D, d'Udekem Y, Ayer J. The Long-Term Management of Children and Adults with a Fontan Circulation: A Systematic Review and Survey of Current Practice in Australia and New Zealand. *Pediatr Cardiol*. 2017; 38(1):56-69.
442. Martinez GJ, Barraclough JY, Nakhla S, Kienzle V, Robertson S, Mallat Z, **Celermajer DS**, Patel S. Neutrophil-derived microparticles are released into the coronary circulation following percutaneous coronary intervention in acute coronary syndrome patients. *Biosci Rep*. 2017; 37(1).
443. Poh CL, Zannino D, Weintraub RG, Winlaw DS, Grigg LE, Cordina R, Hornung T, Bullock A, Justo RN, Gentles TL, Verrall C, du Plessis K, **Celermajer DS**, d'Udekem Y. Three decades later: The fate of the population of patients who underwent the Atriopulmonary Fontan procedure. *Int J Cardiol*. 2017; 231:99-104.
444. Skilton MR, Yeo SQ, Ne JY, **Celermajer DS**, Caterson ID, Lee CM. Weight loss and carotid intima-media thickness-a meta-analysis. *Obesity (Silver Spring)*. 2017;25(2):357-62.
445. Vernon ST, Coffey S, Bhindi R, Soo Hoo SY, Nelson GI, Ward MR, Hansen PS, Asrress KN, Chow CK, **Celermajer DS**, O'Sullivan JF, Figtree GA. Increasing proportion of ST elevation myocardial infarction patients with coronary atherosclerosis poorly explained by standard modifiable risk factors. *Eur J Prev Cardiol*. 2017:2047487317720287.
446. Stanton KM, Ganigara M, Corte P, **Celermajer DS**, McGuire MA, Torzillo PJ, Corte TJ, Puranik R. The Utility of Cardiac Magnetic Resonance Imaging in the Diagnosis of Cardiac Sarcoidosis. *Heart Lung Circ*. 2017.
447. Morrisroe K, Stevens W, Huq M, Prior D, Sahhar J, Ngian GS, **Celermajer D**, Zochling J, Proudman S, Nikpour M. Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension. *Arthritis Res Ther*. 2017;19(1):122.
448. Moonen A, Garsia R, Youssef P, Torzillo P, Corte T, Boehm C, Cordina R, **Celermajer D**, Lau E. Outcomes of pulmonary arterial hypertension therapy in Australia: is monotherapy adequate? *Intern Med J*. 2017.
449. McMullan RL, Fuller NR, Caterson ID, **Celermajer DS**, Gordon A, Hespe C, Hyett JA, O'Reilly CL, Phipps H, Skilton MR. Developmental Origins of Health and Disease: Who knows? Who cares? *J Paediatr Child Health*. 2017;53(6):613-4.
450. Liu J, Drak D, Krishnan A, Chen SY, Canniffe C, Bao S, Denyer G, **Celermajer DS**. Left Ventricular Fibrosis and Systolic Hypertension Persist in a Repaired Aortic Coarctation Model. *Ann Thorac Surg*. 2017.
451. Lau EMT, Giannoulatou E, **Celermajer DS**, Humbert M. Epidemiology and treatment of pulmonary arterial hypertension. *Nat Rev Cardiol*. 2017.

452. Kay S, **Celermajer D**, Vallely M. Structural Heart Disease Australia (SHDA). *Heart Lung Circ.* 2017.
453. Karam N, Narayanan K, Bougouin W, Benameur N, Beganton F, Jost D, Lamhaut L, Perier MC, Cariou A, **Celermajer DS**, Marijon E, Jouven X. Major regional differences in Automated External Defibrillator placement and Basic Life Support training in France: Further needs for coordinated implementation. *Resuscitation.* 2017;118:49-54.
454. Huang L, Schilling C, Dalziel KM, Xie S, **Celermajer DS**, McNeil JJ, Winlaw D, Hornung TS, Radford DJ, Grigg LE, Bullock A, Wheaton GR, Justo RN, Blake J, Bishop R, Du Plessis K, d'Udekem Y. Hospital Inpatient Costs for Single Ventricle Patients Surviving the Fontan Procedure. *Am J Cardiol.* 2017;120(3):467-72.
455. Gnanappa GK, Rashid I, **Celermajer D**, Ayer J, Puranik R. Reproducibility of Cardiac Magnetic Resonance Imaging (CMRI)-Derived Right Ventricular Parameters in Repaired Tetralogy of Fallot (ToF). *Heart Lung Circ.* 2017.
456. Dennis M, Moore B, Kotchetkova I, Pressley L, Cordina R, **Celermajer DS**. Adults with repaired tetralogy: low mortality but high morbidity up to middle age. *Open Heart.* 2017;4(1):e000564.
457. Cistulli PA, **Celermajer DS**. Endothelial Dysfunction and Obstructive Sleep Apnea: The Jury Is Still Out! *Am J Respir Crit Care Med.* 2017;195(9):1135-7.
458. Barraclough JY, Garden FL, Toelle B, O'Meagher S, Marks GB, Cowell CT, **Celermajer DS**, Ayer JG. Sex differences in aortic augmentation index in adolescents. *J Hypertens.* 2017.
459. Arnott C, Cordina R, **Celermajer DS**. The Echocardiographic Characteristics and Prognostic Significance of Pericardial Effusions in Eisenmenger Syndrome. *Heart Lung Circ.* 2017
460. Arnott C, Strange G, Bullock A, Kirby AC, O'Donnell C, Radford DJ, Grigg LE, **Celermajer DS**. Pulmonary vasodilator therapy is associated with greater survival in Eisenmenger syndrome. *Heart.* 2017.
461. **Celermajer D**, Nasir-Ahmad S. Cigarette smoking in Austria - a call for action. *Wien Klin Wochenschr.* 2017.
462. Laohachai K, Winlaw D, Selvadurai H, Gnanappa GK, d'Udekem Y, **Celermajer D**, Ayer J. Inspiratory Muscle Training Is Associated With Improved Inspiratory Muscle Strength, Resting Cardiac Output, and the Ventilatory Efficiency of Exercise in Patients With a Fontan Circulation. *J Am Heart Assoc.* 2017;6(8).
463. Marijon E, **Celermajer DS**, Jouven X. Rheumatic Heart Disease - An Iceberg in Tropical Waters. *N Engl J Med.* 2017;377(8):780-1.
464. Tran DL, Lau EMT, **Celermajer DS**, Davis GM, Cordina R. Pathophysiology of exercise intolerance in pulmonary arterial hypertension. *Respirology.* 2017.
465. Chung K, Strange G, Codde J, **Celermajer D**, Scalia GM, Playford D. Left Heart Disease and Pulmonary Hypertension: Are We Seeing the Full Picture? *Heart Lung Circ.* 2017.

466. Lal S, Kotchetkova I, Cao J, Jackson D, Cordina R, **Celermajer DS**. Heart failure admissions and poor subsequent outcomes in adults with congenital heart disease. *Eur J Heart Fail*. 2017.
467. Lau EMT, **Celermajer DS**, Keogh A, Thakkar V. Screening of Pulmonary Arterial Hypertension. *Semin Respir Crit Care Med*. 2017;38(5):596-605.
468. Moore B, Cao J, Kotchetkova I, **Celermajer DS**. Incidence, predictors and outcomes of infective endocarditis in a contemporary adult congenital heart disease population. *Int J Cardiol*. 2017;249:161-5.
469. Strange G, Lau EM, Giannoulatou E, Corrigan C, Kotlyar E, Kermeen F, Williams T, **Celermajer DS**, Dwyer N, Whitford H, Wrobel JP, Feenstra J, Lavender M, Whyte K, Collins N, Steele P, Proudman S, Thakkar V, Keating D, Keogh A. Survival of Idiopathic Pulmonary Arterial Hypertension Patients in the Modern Era in Australia and New Zealand. *Heart Lung Circ*. 2017.
470. Vaidya K, Arnott C, Martinez GJ, Ng B, McCormack S, Sullivan DR, **Celermajer DS**, Patel S. Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome: A CT Coronary Angiography Study. *JACC Cardiovasc Imaging*. 2017.
471. Bhaskar S, Cordato D, Cappelen-Smith C, Cheung A, Ledingham D, **Celermajer D**, Levi C. Clarion call for histopathological clot analysis in "cryptogenic" ischemic stroke: implications for diagnosis and treatment. *Ann Clin Transl Neurol*. 2017;4(12):926-30.
472. **Celermajer DS**. Atrial septal defects: even simple congenital heart diseases can be complicated. *Eur Heart J*. 2017.
473. Cordina R, Nasir Ahmad S, Kotchetkova I, Eveborn G, Pressley L, Ayer J, Chard R, Tanous D, Robinson P, Kilian J, Deanfield JE, **Celermajer DS**. Management errors in adults with congenital heart disease: prevalence, sources, and consequences. *Eur Heart J*. 2017.
474. Martinez GJ, **Celermajer DS**, Patel S. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. *Atherosclerosis*. 2017.
475. McKenzie KM, Dissanayake HU, McMullan R, Caterson ID, **Celermajer DS**, Gordon A, Hyett J, Meroni A, Phang M, Raynes-Greenow C, Polson JW, Skilton MR. Quantity and Quality of Carbohydrate Intake during Pregnancy, Newborn Body Fatness and Cardiac Autonomic Control: Conferred Cardiovascular Risk? *Nutrients*. 2017;9(12).
476. Moore B, Yu C, Kotchetkova I, Cordina R, **Celermajer DS**. Incidence and clinical characteristics of sudden cardiac death in adult congenital heart disease. *Int J Cardiol*. 2017.
477. Wong J, Chabiniok R, Tibby SM, Pushparajah K, Sammut E, **Celermajer DS**, Giese D, Hussain T, Greil GF, Schaeffter T, Razavi R. Exploring kinetic energy as a new marker of cardiac function in the single ventricle circulation. *J Appl Physiol (1985)*. 2018.
478. Spencer L, Zafiropoulos B, Denniss W, Fowler D, Alison J, **Celermajer D**. Is there a learning effect when the 6-minute walk test is repeated in people with suspected pulmonary hypertension? *Chron Respir Dis*. 2018:1479972317752762.

479. Skoro-Sajer N, Gerges C, Balint OH, Kohalmi D, Kaldararova M, Simkova I, Jakowitsch J, Gabriel H, Baumgartner H, Gerges M, Sadushi-Kolici R, **Celermajer DS**, Lang IM. Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension. *Heart*. 2018.
480. Melehan KL, Hoyos CM, Hamilton GS, Wong KK, Yee BJ, McLachlan RI, O'Meagher S, **Celermajer D**, Ng MK, Grunstein RR, Liu PY. Randomised Trial of CPAP and Vardenafil on Erectile and Arterial Function in Men with Obstructive Sleep Apnea and Erectile Dysfunction. *J Clin Endocrinol Metab*. 2018.
481. Martinez GJ, **Celermajer DS**, Patel S. Reply to: "Inhibitory effects of colchicine on inflammasomes". *Atherosclerosis*. 2018.
482. Martinez GJ, **Celermajer DS**, Patel S. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. *Atherosclerosis*. 2018;269:262-71.
483. Marijon E, **Celermajer DS**, Jouven X. Global Burden of Rheumatic Heart Disease. *N Engl J Med*. 2018;378(1):e2.
484. Gerges C, Gerges M, Fesler P, Maria Pistritto A, Konowitz NP, Jakowitwsch J, **Celermajer DS**, Lang IM. In-depth hemodynamic phenotyping of pulmonary hypertension due to left heart disease. *Eur Respir J*. 2018.
485. Elias P, Poh CL, du Plessis K, Zannino D, Rice K, Radford DJ, Bullock A, Wheaton GR, **Celermajer DS**, d'Udekem Y. Long-term outcomes of single-ventricle palliation for pulmonary atresia with intact ventricular septum: Fontan survivors remain at risk of late myocardial ischaemia and death. *Eur J Cardiothorac Surg*. 2018.
486. Dennis M, Zannino D, du Plessis K, Bullock A, Disney PJS, Radford DJ, Hornung T, Grigg L, Cordina R, d'Udekem Y, **Celermajer DS**. Clinical Outcomes in Adolescents and Adults After the Fontan Procedure. *J Am Coll Cardiol*. 2018;71(9):1009-17.
487. Dennis M, Zannino D, du Plessis K, Bullock A, Disney PJS, Radford DJ, Hornung T, Grigg L, Cordina R, d'Udekem Y, **Celermajer DS**. Clinical Outcomes in Adolescents and Adults After the Fontan Procedure. *J Am Coll Cardiol*. 2018;71(9):1009-17.
488. Cordina R, Ministeri M, Babu-Narayan SV, Ladouceur M, **Celermajer DS**, Gatzoulis MA, Uebing A, Li W. Evaluation of the relationship between ventricular end-diastolic pressure and echocardiographic measures of diastolic function in adults with a Fontan circulation. *Int J Cardiol*. 2018.
489. Cordina R, **Celermajer DS**, d'Udekem Y. Lower limb exercise generates pulsatile flow into the pulmonary vascular bed in the setting of the Fontan circulation. *Cardiol Young*. 2018:1-2.
490. Choteau SA, Cuesta Torres LF, Barraclough JY, Elder AMM, Martinez GJ, Chen Fan WY, Shrestha S, Ong KL, Barter PJ, **Celermajer DS**, Rye KA, Patel S, Tabet F. Transcoronary gradients of HDL-associated MicroRNAs in unstable coronary artery disease. *Int J Cardiol*. 2018;253:138-44.

491. Chong LSH, Fitzgerald DA, Craig JC, Manera KE, Hanson CS, **Celermajer D**, Ayer J, Kasparian NA, Tong A. Children's experiences of congenital heart disease: a systematic review of qualitative studies. *Eur J Pediatr*. 2018;177(3):319-36.
492. Cao JY, Phan K, Ayer J, **Celermajer DS**, Winlaw DS. Long term survival of hypoplastic left heart syndrome infants: Meta-analysis comparing outcomes from the modified Blalock-Taussig shunt and the right ventricle to pulmonary artery shunt. *Int J Cardiol*. 2018;254:107-16.
493. Cao JY, Lee SY, Phan K, Ayer J, **Celermajer DS**, Winlaw DS. Early Outcomes of Hypoplastic Left Heart Syndrome Infants: Meta-Analysis of Studies Comparing the Hybrid and Norwood Procedures. *World J Pediatr Congenit Heart Surg*. 2018;9(2):224-33.
494. Cao, J. Y., Lee, S. Y., Phan, K., Celermajer, D. S., & Lal, S. (2018). Renin-angiotensin-aldosterone inhibition improves right ventricular function: a meta-analysis. *Heart Asia*, 10(1), e010999. doi:10.1136/heartasia-2018-010999
495. Dissanayake, H. U., McMullan, R. L., Gordon, A., Caterson, I. D., Celermajer, D. S., Phang, M., . . . Polson, J. W. (2018). Noninvasive assessment of autonomic function in human neonates born at the extremes of fetal growth spectrum. *Physiol Rep*, 6(8), e13682. doi:10.14814/phy2.13682
496. Garden, F. L., Toelle, B. G., Mihrshahi, S., Webb, K. L., Almqvist, C., Tovey, E. R., . . . Marks, G. B. (2018). Cohort profile: The Childhood Asthma Prevention Study (CAPS). *Int J Epidemiol*. doi:10.1093/ije/dyy078
497. Gerges, C., Gerges, M., Fesler, P., Pistritto, A. M., Konowitz, N. P., Jakowitsch, J., . . . Lang, I. M. (2018). In-depth haemodynamic phenotyping of pulmonary hypertension due to left heart disease. *Eur Respir J*, 51(5). doi:10.1183/13993003.00067-2018
498. Harmer, J. A., Keech, A. C., Veillard, A. S., Skilton, M. R., Watts, G. F., & Celermajer, D. S. (2018). Fenofibrate effects on carotid artery intima-media thickness in adults with type 2 diabetes mellitus: A FIELD substudy. *Diabetes Res Clin Pract*, 141, 156-167. doi:10.1016/j.diabres.2018.05.006
499. Martinez, G. J., Celermajer, D. S., & Patel, S. (2018). Corrigendum to: "The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation" [*Atherosclerosis*. 2018 Feb;269:262-271]. *Atherosclerosis*, 273, 157. doi:10.1016/j.atherosclerosis.2018.03.043
500. Martinez, G. J., Celermajer, D. S., & Patel, S. (2018). Reply to: "Inhibitory effects of colchicine on inflammasomes". *Atherosclerosis*, 273, 155-156. doi:10.1016/j.atherosclerosis.2018.03.042
501. Skoro-Sajer, N., Gerges, C., Gerges, M., Panzenbock, A., Jakowitsch, J., Kurz, A., . . . Lang, I. M. (2018). Usefulness of thrombosis and inflammation biomarkers in chronic thromboembolic pulmonary hypertension-sampling plasma and surgical specimens. *J Heart Lung Transplant*. doi:10.1016/j.healun.2018.04.003
502. Yu, C., Moore, B. M., Kotchetkova, I., Cordina, R. L., & Celermajer, D. S. (2018). Causes of death in a contemporary adult congenital heart disease cohort. *Heart*. doi:10.1136/heartjnl-2017-312777

503. Li, A. M., Celermajer, D. S., Chan, M. H., Sung, R. Y., & Woo, K. S. (2018). Reference range for brachial artery flow-mediated dilation in healthy Chinese children and adolescents. *Hong Kong Med J*, 24 Suppl 3(3), 36-38.
504. Moore, B. M., Cordina, R. L., McGuire, M. A., & Celermajer, D. S. (2018). Efficacy and adverse effects of sotalol in adults with congenital heart disease. *Int J Cardiol*. doi:10.1016/j.ijcard.2018.06.066
505. Morton, J., Bao, S., Vanags, L. Z., Tsatralis, T., Ridiandries, A., Siu, C. W., . . . Bursill, C. A. (2018). Strikingly Different Atheroprotective Effects of Apolipoprotein A-I in Early- Versus Late-Stage Atherosclerosis. *JACC Basic Transl Sci*, 3(2), 187-199. doi:10.1016/j.jacbts.2017.11.004
506. Nasir-Ahmad, S., Cordina, R., Liew, G., McCluskey, P., & Celermajer, D. (2018). The eye in CHD. *Cardiol Young*, 28(8), 981-985. doi:10.1017/s1047951118000859
507. Strange, G., Celermajer, D. S., Marwick, T., Prior, D., Ilton, M., Codde, J., . . . Playford, D. (2018). The National Echocardiography Database Australia (NEDA): Rationale and methodology. *Am Heart J*. doi:10.1016/j.ahj.2018.07.001
508. Wilson, T. G., d'Udekem, Y., Winlaw, D. S., Cordina, R. L., Celermajer, D. S., Wheaton, G. R., . . . Iyengar, A. J. (2018). Hepatic and renal end-organ damage in the Fontan circulation: A report from the Australian and New Zealand Fontan Registry. *Int J Cardiol*. doi:10.1016/j.ijcard.2018.07.118

PEER REVIEW AND INDUSTRY GRANTS OBTAINED

1. Pulmonary endothelial function in children. The Medical Foundation, University of Sydney, 1990-1; \$50,000.
2. In vivo assessment of pulmonary endothelial cell function in children as an early indicator of pulmonary vascular disease. British Heart Foundation, 1991 (with J Deanfield); \$220,000.
3. Non-invasive evaluation of endothelial cell function as an early indicator of arterial disease. Corda, The Heart Charity, 1991; \$110,000.
4. Nitric oxide for pulmonary hypertension in children (with O Miller). British Heart Foundation 1992; \$200,000.
5. The effects of L-arginine on arterial physiology in hypercholesterolaemic young adults. British Heart Foundation 1992 (with J Deanfield); \$170,000.
6. Non-invasive detection of early vascular injury and assessment of reversibility in adults prone to atherosclerosis. National Heart Foundation of Australia Grant-in Aid, 1994; \$70,000.
7. Non-invasive detection of early vascular injury and assessment of reversibility in adults prone to atherosclerosis. National Health and Medical Research Council Project Grant, 1994; \$15,000.
8. R Douglas Wright New Investigator Award, National Health and Medical Research Council, 1994-7; \$253,000.

9. Ian Potter Foundation Fellowship, Royal Australasian College of Physicians, 1994; \$50,000.
10. Non-invasive studies of atherosclerosis. Ramaciotti Foundation, 1994; \$20,000.
11. Lipoprotein oxidation in patients with coronary disease. NHMRC equipment grant 1995 (with R Stocker, W Jessup, D Sullivan); \$11,000.
12. Inhaled nitric oxide in congenital heart disease. Children's Hospital Foundation grant 1995 (with O Miller); \$70,000.
13. Inhaled nitric oxide in congenital heart disease. National Health and Medical Research Council grant 1996 (with O Miller); \$40,000.
14. Medical Foundation Program Grant 1996-2002. The Medical Foundation, University of Sydney; \$1,055,000.
15. ACE inhibitors in diabetic vascular disease - Institute de Recherche Servier; \$100,000. Principal investigators - DS Celermajer, DK Yue.
16. STAID study (Statins In Diabetes)- Merck, Sharpe and Dohme; \$85,000. Principal investigators - DS Celermajer, DK Yue.
17. Effects of Atorvastatin on endothelial function- 6 cities substudy; \$14,000.
18. Effects of Coenzyme Q on vascular function and LDL oxidisability. Blackmores; \$30, 000. Principal investigators - DS Celermajer, R Stocker.
19. The effects of sex steroids on arterial physiology. National Heart Foundation Grant-in-aid, 1996-7; \$72,000.
20. Role of LDL desialylation in atherosclerosis. National Health and Medical research Council grant 1997-9 (with K. Stanley); \$100,000.
21. GTN and the effects on the cell biology of atherosclerosis - Schering Plough; \$60,000. Principal investigators - DS Celermajer, W Jessup.
22. Reversibility of endothelial dysfunction in subjects at risk of atherosclerosis. National Heart Foundation Grant-in-aid,1998-99; \$101,900.
23. Cognitive and psychosocial outcomes following coronary angioplasty versus coronary artery bypass grafting. National Heart Foundation Grant-in-aid, 1998-99; \$60,000.
24. Androgens and atherosclerosis. Merck Medical Schools Grant, 1999-2002; \$155,000 Principal investigators - DS Celermajer, AK Death, DJ Handelsman.
25. Lipid Lowering and Vascular Reactivity, NHF (LIPID substudy); \$42,000.
26. Raloxifene and vascular physiology. Eli Lilly, 1999-2002; \$182,000
27. Strain imaging in the heart. GE – Vingmed, 1999-2002; \$90,000.

28. Effects of repeated hypoxia on cardiovascular physiology (with I Wilcox). Pfizer/Parke-Davis CVL grants, 2000; \$50,000.
29. CATHAY Study (Chinese Atherosclerosis) – Chinese Community Heart Care Association (with KS Woo) – 1999-2000; \$72,000.
30. Vascular reactivity substudy – FIELD (with A Keech); 2000-1; \$180,000.
31. The role of repetitive hypoxia in vascular disease – National Heart Foundation Project Grant (with I Wilcox, R Jeremy), 2001-2; \$68,000.
32. Accelerated atherosclerosis in renal failure. Research Grants Committee, Hong Kong (with KS Woo), 2001-3; \$260,000.
33. Effect of dietary fatty acid supplementation on high density lipoprotein phospholipid composition and endothelial function (with S Nicholls, KA Rye); Cardiovascular Lipid Research Grant 2002; \$55,000.
34. Mechanisms of pro-atherogenic effects of androgens in human vascular cells (with A Death, D Handelsman) – NHMRC 2002-4; \$210,000.
35. The role of physiology of the coronary microcirculation in ischaemic heart disease (with M Adams, J Kilian) – NHF 2002-3; \$80,000.
36. Androgens and atherosclerosis (with A Death, D Handelsman) – NHF 2003-4; \$100,000.
37. Atherosclerosis program grant (Chief Investigators: R Stocker, DS Celermajer, P Barter, K Rye, W Jessup) – NHMRC 2003-2007; \$7,125,500.
38. Fibrosis and diastolic dysfunction in diabetes mellitus (with S Twigg) - Diabetes Australia 2004; \$40,000.
39. CDAH project (with T Dwyer, A Venn) – NHF 2004-5; \$100,000.
40. Nitric oxide and sympathetic reflex control of blood pressure (with V Macefield, M Sanders) – NHF 2006-7; \$120,000.
41. CardioCAPS – a study of omega-3 dietary supplementation in children. CVL grant (with J Ayer) – 2006; \$55,000.
42. Atherosclerosis, Lipoprotein, Cell Biology and Vascular Physiology Program Grant (Chief Investigators: P Barter, DS Celermajer, Kritharides L, K-A Rye, W Jessup) – NHMRC 2008-2012; \$9,870,727.
43. Studies into Pulmonary Vascular Disease. (DS Celermajer, MKC Ng) – NHMRC Project Grant 2008-2010; \$262,500.
44. Atherosclerosis and Vascular Physiology Program Grant (Chief Investigators: P Barter, DS Celermajer, Kritharides L, K-A Rye, W Jessup) – NHMRC 2013-2017; \$7 200 000.
45. Early Detection of Pulmonary Vascular Disease – NHMRC Project Grant 2012 – 2014; \$309,000

46. Survival in Fontan Patients – NHMRC Partnership Grant 2015-2019; \$2,500,000.
47. Progressive Resistance Training for Metabolic Syndrome and Depression Integrated Care: A Randomised Controlled Trial – (Chief Investigators: Y Mavros, M Fiatarone, S Naismith, I Caterson, DS Celermajer), Diabetes Australia 2017; \$60,000
48. Rapid Access Chest Pain Clinic Evaluation- Advanced Health Research Translational Centres Grant – NHMRC (CIA), 2016 – 2017; \$10000
49. NSW Longitudinal Study of First Time Mothers with Heart Disease – CV Research Network (Heart Foundation of Australia); \$150,000

PhD STUDENT SUPPORT GRANTS

1. Mark Adams – NHF - 1995-7; \$50 000.
2. Jane McCrohon – Sydney University - 1996-9; \$58 000.
3. Meredith Sheil – NHF – 1998-2001; \$75 000.
4. Mark Sader – NHF – 1999-2000; \$75 000.
5. Martin Ng – NHMRC – 2000-2; \$75 000.
6. JoDee Lattimore – CSANZ – 2001; \$25 000.
7. Michael Skilton – NHF – 2002-4; \$60 000.
8. Julian Ayers – NHMRC – 2005-7; \$86 000.
9. Sanjay Patel – NHF – 2006-9; \$84 000.
10. Rahn IIsar – NHMRC – 2007-8; \$57 000.
11. Rachael Cordina – NHF – 2009-11; \$78 000.
12. Edmund Lau – NHMRC – 2012-14 - \$93 000

AWARDS FOR RESEARCH

1. 1992 Best Poster Prize, Cardiac Society of Australia and New Zealand. "In vivo detection of endothelial dysfunction in the pulmonary circulation of children with congenital heart disease".
2. 1993 Donald Paterson Prize for Best Original Paediatric Research (British Paediatric Association). "Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis".
3. 1994 Post Doctoral Fellowship, The Medical Foundation, University of Sydney (declined).
4. 1994 Betty Mayne Memorial Award for Best Research Proposal (National Heart Foundation of Australia).
5. 1995 Career Development Award, Royal Prince Alfred Hospital, \$35,000.
6. 1995 Sylvia and Charles Viertel Clinical Investigator Award, \$50,000.

7. 1998 R.T. Hall Prize (awarded by the Cardiac Society of Australia and New Zealand) for “an outstanding contribution to cardiovascular research by a senior investigator”.
8. 1998 Eric Susman Prize (awarded by the Royal Australasian College of Physicians) for “the most outstanding contribution to the knowledge of any branch of internal medicine”.
9. 2002 Commonwealth Health Minister’s Award for Excellence in Health and Medical Research, for outstanding lifetime achievement in health research.
10. 2009 Simon Dack Award for Outstanding Scholarship – from the American College of Cardiology.
11. 2011 “Elite Reviewer” Award, Journal of the American College of Cardiology
12. 2012 NSW Health Minister’s Award for “lifetime contribution to the people of NSW”

COMMERCIALISATION OF RESEARCH

SciCapital – Founder and Chairman of Scientific Advisory Council (ACN 094 561 565).

This company raised over \$4M in Biotechnology support funds and sourced and evaluated over 60 Australian early stage research projects; 8 were funded, including 2 later listed on the ASX.

DC Devices Pty Ltd (Australia); DC Devices Inc (USA) – Founder and Co-Chairman of the Board, Chief Medical Officer (since 2015, CorVia Medical)

DC Devices aims to commercialise a device for the treatment of Heart Failure. Total funding to end 2016 of A\$ 80 million has been obtained.

Carnegie Innovation Fund – Investment Committee, 2010-present

Successful recipient of a Federal Industry Innovation Fund grant of AUS\$20M. This fund of AUS\$40M is responsible for sourcing and commercialising Australian research. David Celermajer is one of four members of the fund’s Investment Committee (with venture capitalists Mark Carnegie and Nicola Young, and StarPharma CEO Jackie Fairley).

The Brain Protection Company

Founder and Chairman since 2015, the BP Company aims to commercialise a device for the treatment of dementia and has raised A\$4m in start up funds (to end 2017).

Industry Consultation, Advisory and Speaking.

Consultant and National/International Advisory Board Member for several major Pharma companies including Pfizer; Merck Sharp and Dohme; AstraZeneca; and Actelion.

Patents

1. Patent application number: PCT/AU2007/001704. 15/05/2008 (World Intellectual Property Organisation). Devices, systems, and methods to treat heart failure. **David Celermajer**.
2. Patent application number: 20100298755. 25/11/2010 (Pittsburgh, PA, USA). Devices, systems, and methods to treat heart failure having an improved flow-control mechanism. Hiroatsu Sugimoto, Edward McNamara, **David Celermajer**, Stephen J. Forucci, Matthew J. Finch.
3. Patent application number: 20100256753. 07/10/2010 (Pittsburgh, PA, USA). Devices, systems, and methods to treat heart failure. Hiroatsu Sugimoto, Edward McNamara, **David Celermajer**, Stephen J. Forucci, Matthew J. Finch.
4. Patent application number: 20100256548. 07/10/2010 (Pittsburgh, PA, USA). Devices, systems, and methods to treat heart failure. Hiroatsu Sugimoto, Edward McNamara, **David Celermajer**, Stephen J. Forucci, Matthew J. Finch.
5. Patent application number: 20100249910. 30/09/2010 (Pittsburgh, PA, USA). Devices, systems, and methods to treat heart failure. Hiroatsu Sugimoto, Edward McNamara, **David Celermajer**, Stephen J. Forucci, Matthew J. Finch.
6. Patent application number: 20100249909. 30/09/2010 (Pittsburgh, PA, USA). Devices, systems, and methods to treat heart failure. Hiroatsu Sugimoto, Edward McNamara, **David Celermajer**, Stephen J. Fortucci, Matthew J. Finch.

“NOT FOR PROFIT” ACTIVITIES

2000-2011	Member, Research Committee, National Heart Foundation of Australia.
2001-2006	Member, Scientific Committee, Cardiac Society of Australia and New Zealand
2005-2011	Chairman, Research Committee, National Heart Foundation of Australia
2006-present	Trustee, Sir Zelman Cowen Universities Fund
2008-2016	Board Member, Menzies School of Health Research (Darwin)
2011-present	Director, Australian Friends of Tel Aviv University
2011-present	Director, Pulmonary Hypertension Society of Australia and New Zealand
2014-present	Rhodes Scholarship Selection Committee (NSW)
2014-present	Board member, Structural Heart Disease, Australia
2017-present	Board member, Heart Kids, Australia
2017-present	Board member, Weizmann, Australia

INVITED PRESENTATIONS – National / International conferences

1. Hypercholesterolaemia and endothelial dysfunction. European Conference on Diabetes and Lipids. Milan, July 1993.
2. Lp(a) and vascular physiology. British Hyperlipidaemia Association, Newcastle Upon Tyne, August 1993.
3. Adult Congenital Heart Disease. Cardiac Society of Australia and New Zealand, Adelaide, August 1994.
4. Non-invasive detection of endothelial dysfunction. Australian Atherosclerosis Society Meeting, Adelaide, September 1994.
5. Non-invasive assessment of early atherosclerosis. ASEANZ Postgraduate Symposium, Sydney, October 1994.
6. Vascular reactivity and its relevance to coronary regression. Lipid Annual Scientific Meeting, Coolum, October 1994.
7. Endothelium and heart disease. South East Asian Myocardial Infarction Symposium, Bali, February 1995.
8. Cellular biology of atherosclerosis. Australasian Cardiology Training Symposium, Sydney, March 1995.
9. Endothelial dysfunction. ASEANZ Lipid Forum, Cebu, Phillipines, May 1995.
10. Primary prevention of coronary disease. ASEANZ Lipid Forum, Cebu, Phillipines, May 1995.
11. Cardiac Ultrasound in the 1990's. CSIRO Ultrasound Symposium, Sydney, May 1995.
12. HDL cholesterol and heart disease. Weekend Specialist Symposium, Sydney, May 1995.
13. Echocardiography in adults with congenital heart disease. Australasian Society of Ultrasound in Medicine, Canberra, August 1995.
14. L-arginine and vascular reactivity. Cardiac Society of Australia and New Zealand, Canberra, August 1995.
15. George Forster Memorial Lecture, Hastings, New Zealand, September 1995.
16. Detection of early atherosclerosis. International Society of Cardiovascular Surgery, Sydney, October 1995.
17. Reversibility of cardiovascular disease. Australian Rehabilitation Society Annual Meeting, Port Stephens, November 1995.
18. Adult congenital heart disease in Australia. American Heart Association Scientific Sessions. Anaheim, California, November 1995.

19. Early Detection of Atherosclerosis. Chinese University of Hong Kong Grand Rounds, Prince of Wales Hospital, Hong Kong, January 1996.
20. Endothelial physiology and coronary heart disease. Guangdong Provincial Cardiovascular Institute, Guangdong, China, January 1996.
21. Endothelium and coronary blood vessels. International Society of Cardiovascular Pharmacology, Sydney, February 1996.
22. Prevention of arterial disease. Indonesian Cardiac Society Meeting, Jakarta, March 1996.
23. The stages of atherogenesis and role of nitric oxide. Specialist Weekend Symposium, Sydney, September 1996.
24. Passive smoking and the cardiovascular system. AMA passive smoking symposium, Canberra, October 1996.
25. The role of the endothelium in atherosclerosis. International Chinese Heart Health Network, Beijing, October 1996.
26. Hormonal influences on arterial physiology. International Women and Heart Disease Symposium, Melbourne, October 1996.
27. Introduction to Vascular Biology. 8th International Menopause Association Meeting, Sydney, November 1996.
28. Clinical assessment of endothelial dysfunction. Endothelial Dysfunction Satellite Symposium, American Heart Association, New Orleans, November 1996.
29. The effects of oral L-arginine on platelet, monocyte and endothelial function in humans. International Vascular Biology Working Group, New Orleans, November 1996.
30. Endothelium, cholesterol and atherosclerosis. Chinese University of Hong Kong, November 1996.
31. Endothelial dysfunction and atherosclerosis. Macao Medical Association, Macao, November 1996.
32. Endothelial function, atherosclerosis and ischaemia. Hong Kong College of Cardiology Annual Scientific Sessions, Hong Kong, April 1997.
33. Paediatric origins of atherosclerosis. World Congress of Paediatric Cardiology, Honolulu, May 1997.
34. Endothelium, hypertension and renal function. International Society of Nephrology, Sydney, May 1997.
35. Tobacco and atherosclerosis. South Pacific Cardiology Congress, Noumea, June 1997.
36. Lipid lowering and vascular reactivity, Cardiac Society of Australia and New Zealand, Hobart, August 1997.

37. Endothelium and atherogenesis. Panhellenic Cardiological Society Annual Meeting, Thessaloniki, Greece, October 1997.
38. Cell biology of endothelial dysfunction. Satellite meeting, American Heart Association, Florida, November 1997.
39. Men, androgens and atherosclerosis. Vascular Biology Working Group, Florida, November 1997.
40. Therapeutic manipulations of the endothelium. Cardiovascular Fellows Foundation, Florida, November 1997.
41. Cholesterol and heart disease. Australian Society for Medical Research Annual Meeting, Adelaide, November 1997.
42. Pathogenesis of unstable coronary artery disease. Far East Lipid Update, Penang, Malaysia, November 1997.
43. Non-invasive detection of atherosclerosis. University Program, Cape Town, South Africa, January 1998.
44. Sex hormones and the cardiovascular system. University Program, Cape Town, South Africa, January 1998.
45. Non-invasive detection of endothelial dysfunction. International Scientific Faculty on the Endothelium, Lucerne, Switzerland, March 1998.
46. Therapeutic manipulations of the nitric oxide pathway. American College of Cardiology Meeting, Atlanta, March 1998.
47. Clinical practice should not be driven by evidence-based medicine. ASEANZ Cardiovascular Forum, Melbourne May 1998.
48. Early origins of adult atherosclerosis. Royal Australasian College of Physicians Annual Scientific meeting, Melbourne, May 1998.
49. Long term outcomes of congenital heart disease. Royal Australasian College of Physicians Annual Scientific Meeting, Melbourne, May 1998.
50. Treatment of atherosclerosis. Grand Rounds, Thong Nhat Hospital, Ho Chi Minh City, May 1998.
51. Role of endothelium in vascular disease. Malaysian Cardiology Update Meeting, Kuala Lumpur, May 1998.
52. Advances in Cardiac Ultrasound. Chinese Echocardiography Users Meeting, Beijing, June 1998.
53. Early atherosclerosis in Chinese. Chinese Echocardiography Users Meeting, Beijing, June 1998.

54. Long term follow up after atrial baffle repair for TGA. Cardiac Society of Australia and New Zealand, Perth, August 1998.
55. The endothelium and cardiovascular risk. Cardiac Society of Australia and New Zealand, Perth, August 1998.
56. The cardiovascular effects of smoking. Cardiac Society of Australia and New Zealand, Perth, August 1998.
57. Androgens and atherosclerosis. Vascular Biology European Meeting, Vienna, August 1998.
58. Non-invasive detection of atherosclerosis. International Society of Cardiac and Vascular Surgery, Brisbane, October 1998.
59. Endothelial function in Chinese. International Vascular Biology Meeting, Dallas, November 1998.
60. Adult congenital heart disease. Innovation and Achievement. Sydney, November 1998.
61. Cardiotoxicity and cigarettes. National Conference on Smoking Cessation. Sydney, December 1998.
62. Atherosclerosis and Inflammation. Thai Atherosclerosis Society, Bangkok, February 1999.
63. Endothelium and Atherosclerosis. Phillipine Lipid Society, Manila, February 1999.
64. Non-invasive detection of early atherosclerosis. International Forum on the Endothelium, Davos, Switzerland, February 1999.
65. Non-invasive detection of endothelial dysfunction. American College of Cardiology sessions, New Orleans, March 1999.
66. Reversibility of smoke-related aretrial damage. Vascular Biology Working Group, New Orleans, March 1999.
67. Gender at the Limits. Cardiology at the Limits Symposium, Cape Town, April 1999.
68. Non-invasive studies of endothelial function. Interamerican Society for Hypertension, Buenos Aires, May 1999.
69. ACE inhibitors and vascular biology. ISCP focus on ACE inhibition. Paris, July 1999.
70. Nitric oxide. Cardiac Society of Australia and New Zealand, Wellington NZ, August 1999.
71. Molecular biology of the vessel wall. Cardiac Society of Australia and New Zealand, Wellington NZ, August 1999.
72. History for the cardiologist. Cardiac Society of Australia and New Zealand, Wellington NZ, August 1999.

73. Diabetes and macrovascular disease. International Diabetes Federation (Western Pacific Region), Sydney, August 1999.
74. Clinical trials are not generally applicable in clinical practice. International Clinical Trials Symposium, Sydney, September 1999.
75. Congenital heart disease. Master Classes in Cardiology, South African Heart Association, George, South Africa, September 1999.
76. Atherosclerosis in young adults. International Olympic Medicine Meeting, Sydney, October 1999.
77. Outlook after congenital heart repair. Paediatric Society of New Zealand (visiting professor), Wellington NZ, November 1999.
78. Advances in pulmonary hypertension. Paediatric Society of New Zealand, Wellington NZ, November 1999.
79. Early detection of atherosclerosis. Paediatric Society of New Zealand, Wellington NZ, November 1999.
80. ACE inhibition and atherogenesis. International tissue ACE symposium, Rome, February 2000.
81. Recent advances in atherosclerosis. Jordanian Cardiac Society, Amman, March 2000.
82. Recent advances in atherosclerosis. Lebanese Heart Association, Beirut, April 2000.
83. Inflammation in coronary disease. WHF Cardiology Year 2000 Course, Beijing and Xian, China, April 2000.
84. The role of antioxidants in atherosclerosis. International Faculty on Endothelial Function, Zurich, June 2000.
85. The effects of risk factors and race on endothelial function. International Atherosclerosis Society, Stockholm, June 2000.
86. Inflammation in atherosclerosis. Le Couer Caledonien, Noumea, June 2000.
87. Benefits of Aggressive Lipid Lowering. Indonesia Atherosclerosis Society, Jakarta August 2000.
88. Benefits of Aggressive Lipid Lowering. Myanmar Medical Association, Yangon, August 2000.
89. Nitric Oxide and Atherosclerosis. Hong Kong College of Cardiology Annual Scientific Sessions, Hong Kong, August 2000.
90. Nitric Oxide and the arterial endothelium. Taiwan Cardiac Society, Taipei, August 2000.
91. The Endothelium and Angiotensin. American Heart Association, New Orleans, November 2000.
92. Sex Steroids and the Heart. South African Heart Association, Stellenbosch, November 2000.

93. Early Detection of Atherosclerosis. South African Heart Association, Stellenbosch, November 2000.
94. Obesity and Vascular Disease. South African Heart Association, Stellenbosch, November 2000.
95. Angiotensin and Vascular Biology. Taiwanese Heart Association Symposium, Taipei, April 2001.
96. Impact of New Diagnostic and Intervention Options on Prognosis in Coronary Disease. International Congress of Life and Health Assurance, Sydney, April 2001.
97. New techniques for detecting coronary atherosclerosis. European Society of Cardiology, Stockholm, August 2001.
98. Brachial artery ultrasound and atherosclerosis. Australasian Society for Ultrasound in Medicine. Sydney, September 2001.
99. Angiotensin II and atherogenesis. Canadian Vascular Biology Working Group, Whistler BC, Canada, January 2002.
100. International Cardiovascular Professor Program – Pfizer Canada – lecture tour of Vancouver, Calgary, Montreal, Toronto and Hamilton – January 2002.
101. Size (of plaque) doesn't matter – the new biology of atherosclerosis. South African Cardiac Society, Botswana, April 2002.
102. Unresolved questions in hypertension. European Stroke Association Annual Scientific Sessions – Geneva, Switzerland, May 2002.
103. Size of plaque and atherosclerosis risk. Hong Kong College of Cardiology Annual General Meeting, June 2002.
104. Non-invasive detection of presymptomatic atherosclerosis. Hong Kong College of Cardiology Annual General Meeting, June 2002.
105. Heart disease in Australia. Royal Society of New South Wales, Mittagong NSW, April 2003.
106. Size of plaque doesn't matter. Eleventh Annual Spring Desert Cardiovascular Update, Tucson Arizona, April 2003.
107. Non-invasive detection of atherosclerosis. Eleventh Annual Spring Desert Cardiovascular Update, Tucson Arizona, April 2003.
108. Ageing and cardiovascular disease. Life Extension Symposium, Sydney, May 2003.
109. Molecular effects of androgens on the vasculature. Cardiology Grand Rounds, Oxford University, July 2003.
110. Sex and the heart. 24th Panhellenic Cardiological Conference, Rhodes Greece, October 2003.

111. ACE-inhibitors and long-term outcomes. Satellite to the American Heart Association, Orlando USA, November 2003.
112. Closing holes in the heart percutaneously – state of the art. SAARC annual scientific sessions, Kathmandu Nepal, February 2004.
113. Following the sick aorta. Cardiac Society of Australia and New Zealand, Brisbane, August 2004.
114. The endothelium for cardiologists. Cardiac Society of Australia and New Zealand, Brisbane, August 2004.
115. Androgens and atherosclerosis. International Society for Heart Research Scientific Sessions, Brisbane, August 2004.
116. Androgens and the heart. Endocrine Society Of Australia, Sydney, August 2004.
117. Cholesterol lowering and atherosclerosis. International Clinical Trials Symposium, Hong Kong, October 2004.
118. Vascular biology and obesity – Keynote Lecture. 6th Hong Kong East Meets West Symposium, Hong Kong, October 2004.
119. Childhood obesity and atherosclerosis – keynote Lecture. South African Heart Association, Durban, October 2004.
120. Following the sick aorta. African Heart Association, Durban, October 2004.
121. Fetal origins of atherosclerosis. African Heart Association, Durban, October 2004.
122. Dual cholesterol inhibition. African Heart Association, Durban, October 2004.
123. Interventions for adults congenital heart disease. African Heart Association, Durban, October 2004.
124. Quality of Life in Pulmonary Hypertension. 4th Scientific Symposium on Endothelin-Related Diseases. Seville, March 2005.
125. Selective endothelin-A antagonism is not superior to dual endothelin antagonism in the treatment of pulmonary artery hypertension. American Thoracic Society annual scientific sessions, San Diego, May 2005.
126. Putting patients first. 2nd Scientific Symposium, Dual ERA. Tokyo, Japan, July 2005.
127. Endothelin and pulmonary hypertension. Australian Pulmonary Hypertension Experts Meeting. Sydney, July 2005.
128. Prevention of long-term cardiovascular disease in children. World Congress of Paediatric Cardiology and Cardiac Surgery, Buenos Aires, Argentina, September 2005.
129. Cardiovascular implications of Childhood Obesity. World Congress of Paediatric Cardiology and Cardiac Surgery, Buenos Aires, Argentina, September 2005.

130. Adult congenital heart disease. Echo Australia Meeting, Sydney, October 2005.
131. Endothelial function in humans. Keynote address, Jagellonian Medical Research Foundation, Poland, May 2006.
132. Physiology of the post-coarctation aorta. Image et Function Seminar, Paris, France, June 2006.
133. How early should we measure endothelial dysfunction? World Congress of Cardiology, Barcelona, September 2006.
134. A new era of management in pulmonary hypertension. World Congress of Cardiology, Barcelona, September 2006.
135. Assessment of endothelial function. State of the Art 2009. World Congress of Paediatric Cardiology, Cairns, June 2009.
136. Eisenmenger's syndrome – role of pulmonary vasodilators. World Congress of Paediatric Cardiology, Cairns, June 2009.
137. Screening for arterial disease of childhood. World Congress of Paediatric Cardiology, Cairns, June 2009.
138. Multidisciplinary clinics for the management of pulmonary hypertension. Australian Pulmonary Hypertension Experts Meeting, Gold Coast, March 2010.
139. Vascular disease in early life. “Masterclasses in cardiology”. INSERM, Paris, March 2010.
140. Pulmonary hypertension in congenital heart disease. 9th International Pulmonary Hypertension Forum, Amsterdam, April 2010.
141. Atheroprevention – state of the art. Europrevent 2010, Prague, May 2010.
142. Early detection and intervention in obesity-related cardiovascular disease in children (Plenary Lecture). Australian and New Zealand Obesity Society Annual Scientific Sessions, Sydney, October 2010.
143. Moderator, Fetal origins of cardiovascular disease expert session. American Heart Association Scientific Sessions, Chicago, November 2010.
144. Austin Doyle Plenary Lecture. High Blood Pressure Council of Australia, Melbourne, December 2010.
145. Pulmonary hypertension with surgical AP shunts. 10th International Pulmonary Hypertension Experts Meeting, Munich, March 2011.
146. Early Detection of Atherosclerosis. Queenstown Heart Meeting, NZ, August 2011.
147. 3D Echo for Adult Congenital Heart Disease. American Heart Association Annual Scientific Sessions, Orlando, Florida, November 2011.

148. Endothelium and atherosclerosis. International Society of Atherosclerosis, Sydney March 2012.
149. Pulmonary Hypertension in Congenital Heart Disease, 11th International PHT Symposium – Dublin, May 2012.
150. Early Detection of Pulmonary Vascular Disease. Grand Rounds, St Thomas Hospital, London, May 2014.
151. Exercise in Children with Heart Disease. Grand Rounds, Evelina Children’s Hospital, London, June 2014.
152. Advances in Diastolic Heart Failure. Keynote Speaker, Clinical Governance Meeting, Royal Brompton Hospital, London, July 2014.
153. Congenital Heart Disease and Pulmonary Artery Hypertension. The ANZ Registry, Pulmonary Hypertension Society of ANZ Annual Scientific meeting, Gold Coast Queensland, October 2014.
154. Congenital heart Disease in Adults. Keynote address, HeartKids annual meeting, Sydney, February 2015.
155. Early Detection Of Pulmonary vascular disease. Grand Rounds, South Australian health and medical research Institute, Adelaide February 2015.
156. Novel advances in the diagnosis of PHT. Thoracic Society of Australia, Sydney, March 2015.
157. Ebstein’s anomaly in Adults. Cardiac Society of ANZ, Melbourne August 2015.
158. Transition from paediatric to adult care in CHD. Cardiac Society of ANZ, Melbourne August 2015.
159. Definition and classification of pulmonary hypertension. 7th annual Central European PH meeting, Vienna, Austria, November 2015.
160. Interventions and Imaging – the Fontan circulation. Euro Echo Imaging 2015 – Seville, Spain, December 2015.
161. Tricuspid Valve Pathologies. Structural Heart Disease of Australia, Sydney, February 2016.
162. Left Atrial Decompression, Structural Heart Disease of Australia, Melbourne, July 2016.
163. Pregnancy in Congenital Heart Disease. Cardiac Society of ANZ, Adelaide, August 2016.
164. The Role of Mathematics in Health Research, The A.L Blakers (Academy of Sciences) Lecture, National Mathematics, Summer School, Canberra, January 2017.
165. New Frontiers in Early Diagnosis of Pulmonary Vascular Disease. PHT Academy, Vienna, June 2017.
166. Childhood Obesity and Endothelial Dysfunction. World Congress of Pediatric Cardiology, Barcelona, July 2017.

CLINICAL AND ADMINISTRATIVE RESPONSIBILITIES

CURRENT CLINICAL DUTIES

Adult Congenital Heart Disease – Director of Services

Transthoracic and transoesophageal echocardiography (director of service at RPAH)

Inpatient care; Coronary Care Unit, Cardiology Wards

Cardiology consultations

Outpatient care; particularly for young adults with congenital heart disease and patients with pulmonary hypertension

Diagnostic and therapeutic cardiac catheterisation

ADMINISTRATION

Member of Organising Committee, International Society of Cardiovascular Pharmacology, Sydney 1996

Member of Organising Committee, Australian Atherosclerosis Society 1995, 1997

Member of Department of Cardiology Forward Planning Committee, 1995-1999

Chairman - Faculty Futures Committee, University of Sydney, 1998-1999

Member of Registrar Selection Committee, RPA Hospital, 1994-2000

Interviewer, Graduate Medical Program, University of Sydney 1996-2000

Secretary, International Society for Adult Congenital Cardiac Disease – 1998-2000

Member - Postgraduate Medical Education Committee, 1998-2000

Chairman – Research Executive Committee, RPA Hospital, 1999-2001

Member – Commonwealth Health Innovation Forum III – Organising Committee – 2001

Member of Council, Sydney Health and Biotechnology Alliance – from 2001

Member of Organising Committee, ASEANZ 1997-8; 2003-2006; Chairman 1999-2002

Member - Research Development Committee, University of Sydney, 1999-2002

Deputy Chairman – Scientific Organising Committee – World Congress of Cardiology (Sydney, 2002)

Member – NHF National Research Committee – 2000-2002

Member - Medical and Scientific Advisory Committee, National Heart Foundation 1996-2004

Member - National Tobacco Control Committee, National Heart Foundation - 1997-2004

Editor – RPA Research Annual Report, 2000-2004

Director of Research – RPA Hospital, 2000-2004

Chairman - NHF Research Grants Interviews Committee – 2001-2004

Preparation of the Department of Cardiology Research Reports, 1994-2006

Member – Scientific Committee, Cardiac Society of Australia and New Zealand, 2002-2006

Chairman – NHF Research Committee, from 2006

Member of Organising Committee, Image et Fonction - Paris, 2006

Member – Steering Committee, Australian Scleroderma Interest Group, from 2006

Director of Echocardiography - RPA Hospital- 1998-present

Director of Adult Congenital Heart Disease Services – RPA Hospital- 1999-present

Director of Pulmonary Hypertention Services- RPA Hospital-2005-present

MEMBERSHIPS OF MEDICAL SOCIETIES

Royal Australasian College of Physicians
RPA Hospital Medical Board
The Children's Hospital Medical Board
Cardiac Society of Australia and New Zealand
Australasian Society for Medical Research
International Society of Adult Congenital Cardiac Disease
American Heart Association Council on Circulation (elected to Fellowship in 1997)

EXTRA-CURRICULAR ACTIVITIES

DEBATING AND PUBLIC SPEAKING

1978 Sydney Grammar School Firsts (Captain)
GPS Firsts (Captain)
N.S.W. Schools Debating Team

1980 - 1983 N.S.W. Adult Debating Team

1983 Australian Adult Debating Team
BEST SPEAKER - WORLD DEBATES TOURNAMENT
Princeton, New Jersey

1984 BEST DEBATER & WINNING TEAM - WORLD DEBATING CHAMPIONSHIP,
Edinburgh, Scotland
WORLD PUBLIC SPEAKING CHAMPION Edinburgh, Scotland

1985-2017 Frequent participation in debates (medical and non-medical)

Other Major Activities – Undergraduate/Postgraduate

1978 Editor of "Alligator" magazine, Sydney Grammar School
1978 Committee member of "The Sydneian" magazine, Sydney Grammar School
1981 Medical Revue - Sydney University - writer/producer/performer
1983 Australasian representative on World Debates Council
1986 - 1987 President of Resident Medical Officers' Association, RPAH

SPORTS

1977 Member - G.P.S. First XI Soccer
1978 Captain - Sydney Grammar School First XI Soccer
1978 - 2007 Member of Australian Golf Club
1983 Captain/Coach Sydney University Medicine
Soccer First XI
1984 Representative of Royal Prince Alfred
Hospital in Rugby, Golf and Cricket
1985 Representative for Oxford University in Rugby

Current Interests Australian art, theatre, golf, exercise